FR18C1021I2 - Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle - Google Patents

Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle

Info

Publication number
FR18C1021I2
FR18C1021I2 FR18C1021C FR18C1021C FR18C1021I2 FR 18C1021 I2 FR18C1021 I2 FR 18C1021I2 FR 18C1021 C FR18C1021 C FR 18C1021C FR 18C1021 C FR18C1021 C FR 18C1021C FR 18C1021 I2 FR18C1021 I2 FR 18C1021I2
Authority
FR
France
Prior art keywords
regulating
activity
functional molecule
immunologically functional
immunologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR18C1021C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14346708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1021(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of FR18C1021I1 publication Critical patent/FR18C1021I1/fr
Application granted granted Critical
Publication of FR18C1021I2 publication Critical patent/FR18C1021I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
FR18C1021C 1999-04-09 2018-05-17 Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle Active FR18C1021I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10315899 1999-04-09
EP00915403.0A EP1176195B1 (en) 1999-04-09 2000-04-07 Method for controlling the activity of immunologically functional molecule

Publications (2)

Publication Number Publication Date
FR18C1021I1 FR18C1021I1 (fr) 2018-07-13
FR18C1021I2 true FR18C1021I2 (fr) 2020-09-04

Family

ID=14346708

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1021C Active FR18C1021I2 (fr) 1999-04-09 2018-05-17 Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle

Country Status (14)

Country Link
US (15) US7214775B2 (show.php)
EP (11) EP2270148A3 (show.php)
JP (3) JP4368530B2 (show.php)
AU (1) AU3672800A (show.php)
BE (1) BE2018C020I2 (show.php)
CA (2) CA2369292C (show.php)
CY (4) CY1114164T1 (show.php)
DK (8) DK2275541T3 (show.php)
ES (9) ES2420835T3 (show.php)
FR (1) FR18C1021I2 (show.php)
LU (1) LUC00074I2 (show.php)
NL (1) NL300939I2 (show.php)
PT (2) PT1914244E (show.php)
WO (1) WO2000061739A1 (show.php)

Families Citing this family (1778)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6693176B1 (en) * 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
AU2016204535C1 (en) * 2000-04-12 2017-02-23 Laboratoire Français Du Fractionnement Et Des Biotechnologies Anti-D monoclonal antibodies
US20060034828A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060024304A1 (en) * 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7863020B2 (en) * 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
ATE309385T1 (de) * 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US20060034830A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03002974A (es) * 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
US20050144670A1 (en) * 2001-03-06 2005-06-30 Kazuhito Fujiyama Plant cell having animal-type sugar chain adding function
NZ532526A (en) * 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
WO2003049704A2 (en) * 2001-12-11 2003-06-19 University Of Massachusetts Antibodies to treat cancer
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
MXPA04006357A (es) 2001-12-27 2005-03-31 Glycofi Inc Metodos para disenar estructuras de carbohidrato del tipo de mamifero.
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
MXPA04009924A (es) * 2002-04-09 2005-07-01 Kyowa Hakko Kogyo Kk Celulas de genoma modificado.
WO2003084569A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
JPWO2003085118A1 (ja) * 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
AU2003236019A1 (en) * 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
JP4628679B2 (ja) * 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
US20040259150A1 (en) * 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
US20040115204A1 (en) * 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
WO2004081048A1 (ja) 2003-03-13 2004-09-23 Chugai Seiyaku Kabushiki Kaisha 変異受容体に対するアゴニスト活性を有するリガンド
EP1613654A2 (en) * 2003-04-03 2006-01-11 Laboratoire Français du Fractionnement et des Biotechnologies Antibodies with enhanced ability to immunomodulate cell functions
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
ES2348008T3 (es) 2003-06-18 2010-11-26 Chugai Seiyaku Kabushiki Kaisha Transportador de fucosa.
AU2004256354B2 (en) 2003-07-15 2011-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
JP4643450B2 (ja) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
EP1666501A4 (en) 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd ANTI-HM1.24 ANTIBODIES WITH MODIFIED SUGAR CHAIN
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
CA2542042A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Antibody composition specifically binding to il-5 receptor
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
CA2542037A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition of antibody capable of specifically binding ccr4
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
AU2004280065A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
AU2004280066A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell
US20060021071A1 (en) * 2003-10-09 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. Cell in which genome is modified
AU2004280064A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell neutralized to serum-free system
ATE518888T1 (de) 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
WO2005053742A1 (ja) * 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
SI2383295T1 (sl) 2003-12-10 2015-07-31 E.R. Squibb & Sons, L.L.C. Protitelesa IP-10 in njihova uporaba
KR101151477B1 (ko) 2003-12-10 2012-06-22 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
EP2241331A3 (en) * 2003-12-15 2011-03-09 Alexion Pharmaceuticals, Inc. Novel anti-DC-SIGN antibodies
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
JP2005224240A (ja) * 2004-01-13 2005-08-25 Kyowa Hakko Kogyo Co Ltd ノックアウト非ヒト動物から樹立された不死化細胞株
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
AU2005224672B2 (en) * 2004-03-17 2011-06-02 Glycofi, Inc. Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
AR049292A1 (es) * 2004-06-04 2006-07-12 Genentech Inc Metodo para tratar lupus con un anticuerpo cd20
AU2005249566B2 (en) 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
JP5160887B2 (ja) 2004-06-21 2013-03-13 メダレックス インコーポレイテッド インターフェロンアルファレセプター１抗体及びその使用法
PT1674111E (pt) 2004-07-09 2010-12-15 Chugai Pharmaceutical Co Ltd Anticorpo anti-glipicano 3
CA2573505C (en) 2004-07-14 2013-06-25 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
KR20130103580A (ko) 2004-08-24 2013-09-23 추가이 세이야쿠 가부시키가이샤 항 글리피칸 3 항체를 이용한 어쥬번트 요법
ZA200702335B (en) 2004-10-05 2009-05-27 Genentech Inc Method for treating vasculitis
AU2005297772B2 (en) * 2004-10-26 2011-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
CN102746404B (zh) 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
WO2006082515A2 (en) 2005-02-07 2006-08-10 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
KR101289537B1 (ko) 2005-02-15 2013-07-31 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
EP1851251A2 (en) * 2005-02-18 2007-11-07 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
EA037929B1 (ru) 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
WO2006110585A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN101223448B (zh) 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
BRPI0611714A2 (pt) 2005-06-30 2009-01-13 Abbott Lab proteÍnas de ligaÇço a il-12/p40
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
EP2500357A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NO345919B1 (no) 2005-08-26 2021-10-18 Roche Glycart Ag Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet
JP2009508476A (ja) * 2005-08-31 2009-03-05 セントカー・インコーポレーテツド 高められたエフェクター機能をもつ抗体定常領域の製造用の宿主細胞株
WO2007028144A2 (en) * 2005-09-02 2007-03-08 Glycofi, Inc Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
EP1937305A4 (en) * 2005-09-09 2008-10-08 Glycofi Inc IMMUNOGLOBULIN CONTAINING PRESENTLY A MAN7GLCNAC2, MAN8GLCNAC2 GLYCOFORM
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
JPWO2007046439A1 (ja) 2005-10-18 2009-04-23 独立行政法人農業生物資源研究所 抗体を産生するトランスジェニックカイコとその製造方法
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
ES2376083T3 (es) 2005-10-21 2012-03-08 Genzyme Corporation Terapéuticos basados en anticuerpos con actividad adcc mejorada.
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
EP2455100A3 (en) * 2005-11-07 2012-11-07 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
EP1954719A2 (en) 2005-12-02 2008-08-13 Genentech Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
JP5512128B2 (ja) 2005-12-08 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー フコシルｇｍ１に対するヒトモノクローナル抗体および抗フコシルｇｍ１を使用するための方法
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
CN101351475B (zh) 2005-12-30 2013-05-15 默克专利有限公司 具有提高的稳定性的白细胞介素12p40变体
AU2007204777B2 (en) * 2006-01-04 2011-12-01 Novartis Ag Antibody-dependent cellular cytotoxicity assay
JP5164856B2 (ja) 2006-01-05 2013-03-21 ジェネンテック， インコーポレイテッド 抗ｅｐｈｂ４抗体およびその使用方法
NZ598048A (en) 2006-01-17 2013-05-31 Synthon Biopharmaceuticals Bv Compositions and methods for humanization and optimization of n-glycans in plants
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
EP2397148A3 (en) 2006-02-02 2012-04-25 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
WO2007109376A2 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
US20080014203A1 (en) * 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8524865B2 (en) 2006-05-30 2013-09-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CA2654304A1 (en) * 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
CL2007001623A1 (es) 2006-06-06 2008-01-18 Genentech Inc Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo.
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
AU2007275654A1 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania WSX-1/p28 as a target for anti-inflammatory responses
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
EP2050466B1 (en) 2006-08-14 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
HRP20140331T1 (hr) 2006-08-14 2014-05-09 Xencor, Inc. Optimizirana antitijela usmjerena na cd19
EA200970250A1 (ru) 2006-09-05 2010-02-26 Медарекс, Инк. Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
MX2009002414A (es) 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
KR101625961B1 (ko) 2006-09-08 2016-05-31 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
ES2620261T3 (es) 2006-09-10 2017-06-28 Glycotope Gmbh Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
JP5562031B2 (ja) 2006-09-18 2014-07-30 ゼンコー・インコーポレイテッド Ｈｍ１．２４を標的とする最適化抗体
ME02269B (me) 2006-10-02 2016-04-28 Medarex Inc Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
UA94484C2 (uk) 2006-10-12 2011-05-10 Дженентек, Інк. Антитіла до лімфотоксину-альфа
WO2008047723A1 (fr) 2006-10-12 2008-04-24 Forerunner Pharma Research Co., Ltd. Diagnostic et traitement du cancer à l'aide d'un anticorps anti-ereg
EP3040347A3 (en) 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
MX2009003938A (es) 2006-10-27 2009-04-24 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
CL2007003291A1 (es) 2006-11-15 2008-07-04 Medarex Inc Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
KR20150067395A (ko) 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
US20080127996A1 (en) * 2006-12-04 2008-06-05 Weinhold Dennis G Method and apparatus to remediate an acid and/or liquid spill
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
US20110236374A1 (en) 2007-01-24 2011-09-29 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
MX2009008430A (es) 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
DK2447719T3 (en) 2007-02-26 2016-10-10 Oxford Biotherapeutics Ltd proteins
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
RU2479629C2 (ru) * 2007-03-07 2013-04-20 Гликофи, Инк. Продукция гликопротеинов с модифицированным фукозилированием
CN101641115B (zh) 2007-03-08 2013-04-24 卡罗拜奥斯制药公司 用于实体瘤治疗的EphA3抗体
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008143878A1 (en) 2007-05-14 2008-11-27 Medimmune, Llc Methods of reducing eosinophil levels
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
MX2009013816A (es) 2007-06-21 2010-02-24 Macrogenics Inc Diacuerpos covalentes y usos de los mismos.
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
JP5469456B2 (ja) 2007-06-25 2014-04-16 中外製薬株式会社 ＡＤＣＣ活性又はＣＤＣ活性を有する抗Ｐｒｏｍｉｎｉｎ−１抗体
CA2691734A1 (en) * 2007-07-04 2009-01-08 Forerunner Pharma Research Co., Ltd. Anti-muc17 antibody
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
EP2178916B1 (en) * 2007-07-31 2014-12-17 Regeneron Pharmaceuticals, Inc. Human antibodies to human cd20 and method of using thereof
US8501907B2 (en) 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
ES2719728T3 (es) 2007-09-04 2019-07-12 Compugen Ltd Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
DK2205258T3 (en) 2007-09-28 2017-08-28 Janssen Biotech Inc Method and structural conformations of antibody preparations with increased resistance to proteases
KR20150126724A (ko) * 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2009056634A2 (en) 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
WO2009062102A2 (en) 2007-11-07 2009-05-14 Genentech, Inc. Compositions and methods for treatment of microbial disorders
CN104109208A (zh) 2007-11-14 2014-10-22 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
KR101615935B1 (ko) 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
EP2245064B1 (en) 2007-12-21 2014-07-23 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
CA2711557A1 (en) 2008-01-11 2009-07-16 The University Of Tokyo Anti-cldn6 antibody
ES2613963T3 (es) 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio
CA2714071A1 (en) 2008-02-05 2009-08-13 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
PL2250279T3 (pl) 2008-02-08 2016-11-30 Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
PT2247304T (pt) 2008-04-02 2016-08-29 Macrogenics Inc Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
JP5522405B2 (ja) 2008-04-25 2014-06-18 協和発酵キリン株式会社 安定な多価抗体
EP2899209A1 (en) 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
WO2009133208A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
CA2723219A1 (en) 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
EP2283862B1 (en) 2008-06-02 2018-08-08 The University of Tokyo Combination treatment of cancer comprising anti-mfg-e8 antibody
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
CA2726845C (en) 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
CN102007147B (zh) 2008-06-30 2014-11-05 协和发酵麒麟株式会社 抗cd27抗体
KR101054362B1 (ko) * 2008-07-03 2011-08-05 재단법인 목암생명공학연구소 재조합 단백질의 푸코스 함량을 감소시키는 방법
BRPI0915825A2 (pt) 2008-07-08 2015-11-03 Abbott Lab proteínas de ligação à prostaglandina e2 usos das mesmas
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
DK2733492T3 (en) 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
BRPI0916668B1 (pt) 2008-08-05 2021-12-28 Novartis Ag Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010018846A1 (ja) * 2008-08-13 2010-02-18 協和発酵キリン株式会社 ガングリオシドgm2に特異的に結合する抗体組成物を含む医薬
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
EP3190128B1 (en) 2008-09-17 2018-11-14 Xencor, Inc. Compositions and methods for treating ige-mediated disorders
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
JP2012503656A (ja) 2008-09-26 2012-02-09 エウレカ セラピューティクス，インコーポレイテッド 変異体グリコシル化パターンを有する細胞株およびタンパク質
EP3524620A1 (en) * 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
GB2466025A (en) 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
EP3482769B1 (en) 2008-12-19 2024-05-29 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US8846870B2 (en) 2008-12-22 2014-09-30 Chugai Seiyaku Kabushiki Kaisha Anti-HS6ST2 antibodies and uses thereof
KR20170143025A (ko) 2008-12-23 2017-12-28 제넨테크, 인크. 단백질 ａ에 대해 변경된 결합을 갖는 이뮤노글로불린 변이체
WO2010073694A1 (ja) 2008-12-25 2010-07-01 国立大学法人東京大学 抗tm4sf20抗体を用いた癌の診断と治療
PT2374883T (pt) 2008-12-26 2016-10-20 Kyowa Hakko Kirin Co Ltd Anticorpo anti-cd4
KR20110099762A (ko) 2008-12-26 2011-09-08 고쿠리츠다이가쿠호우진 도쿄다이가쿠 항ｌｇｒ７항체를 사용하는 암의 진단 및 치료
US9181341B2 (en) 2009-01-19 2015-11-10 Innate Pharma Anti-KIR3D antibodies
WO2010084408A2 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
UA102891C2 (uk) 2009-03-05 2013-08-27 Медарекс, Інк. Повні людські антитіла, специфічні до cadm1
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
EP2403879A1 (en) 2009-03-06 2012-01-11 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
SG174904A1 (en) 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
CA2757531A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
SI2417156T1 (sl) 2009-04-07 2015-06-30 Roche Glycart Ag Trivalentna, bispecifiäśna protitelesa
SG175078A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
CN106317224B (zh) 2009-04-09 2020-05-12 第一三共株式会社 抗-Siglec-15抗体
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
JP5746018B2 (ja) 2009-04-16 2015-07-08 国立大学法人 東京大学 抗ｔｍｐｒｓｓ１１ｅ抗体を用いた癌の診断と治療
CA2759146C (en) 2009-04-20 2017-06-13 Kyowa Hakko Kirin Co., Ltd. Agonist anti-cd40 antibody
MA33276B1 (fr) 2009-04-20 2012-05-02 Oxford Biotherapeutics Ltd Anticorps spécifiques à la cadhérine-17
MX2011011338A (es) 2009-04-27 2012-04-19 Novartis Ag Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
SG174273A1 (en) 2009-04-27 2011-10-28 Novartis Ag Compositions and methods for increasing muscle growth
PL2426148T3 (pl) 2009-04-27 2016-01-29 Kyowa Hakko Kirin Co Ltd Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
KR20120024763A (ko) 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
EP2435476A4 (en) 2009-05-27 2013-04-17 Synageva Biopharma Corp ANTIBODIES OBTAINED FROM BIRDS
CN102448985B (zh) 2009-05-27 2015-08-05 霍夫曼-拉罗奇有限公司 三或四特异性抗体
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
ES2527173T3 (es) 2009-06-02 2015-01-21 Regeneron Pharmaceuticals, Inc. Células de fucosilación deficiente
KR101812348B1 (ko) 2009-06-11 2017-12-26 다이가쿠쿄도리요우키칸호우진 죠우호우시스테무 겡큐키코우 단백질의 생산 방법
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
RU2011151287A (ru) 2009-06-18 2013-07-27 Пфайзер Инк. АНТИ Notch-1 АНТИТЕЛА
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
SG178177A1 (en) 2009-07-31 2012-03-29 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
ES2661601T3 (es) 2009-08-07 2018-04-02 Kyowa Hakko Kirin Co., Ltd. Anticuerpo humanizado antioligómero de amiloide-beta
EP2463369A4 (en) 2009-08-07 2013-09-18 Kyowa Hakko Kirin Co Ltd HUMANIZED ANTIBODIES AGAINST AMYLOID B OLIGOMERS
WO2011018225A1 (en) 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2771436A1 (en) 2009-08-17 2011-02-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
AU2010288469A1 (en) 2009-08-31 2012-03-01 Roche Glycart Ag Affinity-matured humanized anti CEA monoclonal antibodies
RU2012112550A (ru) 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
MX2012003396A (es) 2009-09-16 2012-04-10 Genentech Inc Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
PT2488554T (pt) 2009-10-14 2019-09-13 Humanigen Inc Anticorpos para epha3
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2010310585A1 (en) 2009-10-22 2012-05-03 Genentech, Inc. Anti-hepsin antibodies and methods using same
CA3031851C (en) 2009-10-23 2020-07-07 Amgen British Columbia Anti-gcc antibody molecules and related compositions and methods
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
ES2622366T3 (es) 2009-10-26 2017-07-06 F. Hoffmann-La Roche Ag Procedimiento para la producción de una inmunoglobulina glucosilada
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112012010252A2 (pt) 2009-10-29 2016-12-06 Janssen Biotech Inc variantes de glicosilação de anticorpo
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
CA2780143A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
BR112012013734A2 (pt) 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
WO2011076781A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
SI2516469T1 (sl) 2009-12-22 2016-05-31 Roche Glycart Ag Protitelesa proti her3 in uporabe le-teh
RU2559542C2 (ru) 2009-12-23 2015-08-10 Дженентек, Инк. Антитела против bv8 и их применение
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
PL2530091T3 (pl) 2010-01-29 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
AU2011214465A1 (en) 2010-02-10 2012-08-30 Novartis Ag Methods and compounds for muscle growth
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
SI2535358T1 (en) 2010-02-10 2018-03-30 Fujifilm Ri Pharma Co., Ltd. Anti-cadherin antibody, labeled with radioactive metal
SG183333A1 (en) 2010-02-18 2012-09-27 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
EP2536761B1 (en) 2010-02-19 2017-09-20 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
EP2540827A4 (en) 2010-02-26 2013-09-04 Chugai Pharmaceutical Co Ltd ANTI-ICAM3 ANTIBODIES AND USE THEREOF
WO2011108502A1 (ja) 2010-03-02 2011-09-09 協和発酵キリン株式会社 改変抗体組成物
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
JP6093692B2 (ja) 2010-03-24 2017-03-08 ジェネンテック， インコーポレイテッド 抗ｌｒｐ６抗体
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
CA3079122A1 (en) 2010-03-26 2011-09-29 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
WO2011118739A1 (ja) 2010-03-26 2011-09-29 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
EP2552957A4 (en) 2010-03-29 2013-11-20 Zymeworks Inc ANTIBODIES WITH REINFORCED OR SUPPRESSIVE ACTIVE FUNCTION
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
CN102844049B (zh) 2010-04-27 2016-06-01 罗切格利卡特公司 无岩藻糖基化CD20抗体与mTOR抑制剂的联合疗法
WO2011138392A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
PE20130206A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
US9169329B2 (en) 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
AU2011261362B2 (en) 2010-06-03 2016-06-09 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
CN103079644B (zh) * 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
JP5940061B2 (ja) 2010-06-18 2016-06-29 ジェネンテック， インコーポレイテッド 抗ａｘｌ抗体及び使用方法
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
EP2585476A4 (en) 2010-06-22 2014-01-22 Neogenix Oncology Inc ANTIGENS AND ANTIBODIES SPECIFIC TO COLON AND PANCREATIC CANCER
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
WO2012001073A2 (en) 2010-07-01 2012-01-05 Glaxo Group Limited Improved method for selecting high producing cell lines
WO2012005076A1 (ja) 2010-07-08 2012-01-12 本田技研工業株式会社 高周波加熱用コイル
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
RU2571226C2 (ru) 2010-07-09 2015-12-20 Дженентек, Инк. Антитела против нейропилина и способы их применения
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
CN103052649B (zh) 2010-07-29 2015-12-16 Xencor公司 具有修改的等电点的抗体
US20140308699A1 (en) 2010-07-30 2014-10-16 Glycode Yeast artificial chromosome carrying the mammalian glycosylation pathway
CN103154025B (zh) 2010-08-02 2015-07-01 宏观基因有限公司 共价双抗体及其用途
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2013106216A (ru) 2010-08-03 2014-09-10 Ф. Хоффманн-Ля Рош Аг Биомаркеры хронической лимфоцитарной лейкемии
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
WO2012017003A1 (en) 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
HUE036077T2 (hu) 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
CA2806640A1 (en) 2010-08-13 2012-02-16 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
RU2013110874A (ru) 2010-08-25 2014-09-27 Ф.Хоффманн-Ля Рош Аг Антитела против il-18r1 и их применения
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
SG187965A1 (en) 2010-08-27 2013-04-30 Stem Centrx Inc Notum protein modulators and methods of use
JP2013537966A (ja) 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド バイオマーカー及び治療の方法
SG10201506959SA (en) 2010-09-03 2015-10-29 Stemcentrx Inc Novel modulators and methods of use
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
EP2622091B1 (en) 2010-09-23 2019-03-13 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
HRP20160584T1 (hr) 2010-10-29 2016-06-17 Daiichi Sankyo Company, Limited Novo anti-dr5 antitijelo
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
WO2012064836A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US20120269834A1 (en) * 2010-11-19 2012-10-25 Robert Jordan Immunoglobulin cleavage fragment vaccine compositions
EP2643016A2 (en) 2010-11-23 2013-10-02 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
LT2643352T (lt) 2010-11-23 2018-08-10 Glaxo Group Limited Antigeną onkostatiną m (osm) surišantys baltymai
WO2012069557A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
PE20140673A1 (es) 2010-12-08 2014-06-14 Stem Centrx Inc Nuevos moduladores y metodos para su uso
KR101026999B1 (ko) 2010-12-08 2011-04-11 재단법인 목암생명공학연구소 재조합 단백질의 푸코스 함량을 감소시키는 방법
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
US9410176B2 (en) 2010-12-15 2016-08-09 Inter-University Research Institute Corporation Research Organization Of Information And Systems Method for producing proteins
KR101580726B1 (ko) 2010-12-15 2015-12-29 와이어쓰 엘엘씨 항-노치1 항체
CN107312796A (zh) 2010-12-15 2017-11-03 大学共同利用机关法人情报·系统研究机构 蛋白质的生产方法
EP3447491A3 (en) 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnosis and treatments relating to th2 inhibition
CA2819436A1 (en) 2010-12-16 2012-06-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
TWI477513B (zh) 2010-12-20 2015-03-21 建南德克公司 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物
KR20130133247A (ko) 2010-12-21 2013-12-06 애브비 인코포레이티드 Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
CA2820953A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP6012624B2 (ja) 2010-12-23 2016-10-25 ヤンセン バイオテツク，インコーポレーテツド 活性プロテアーゼ耐性抗体Ｆｃ突然変異体
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
FR2971250A1 (fr) 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
JP2014511147A (ja) 2011-02-10 2014-05-12 ロシュ グリクアート アーゲー 改善された免疫療法
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
BR112013020338A2 (pt) 2011-02-28 2016-10-18 Hoffmann La Roche proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
AU2012222463B9 (en) 2011-03-02 2017-05-25 Roche Glycart Ag CEA antibodies
JP2014509864A (ja) 2011-03-23 2014-04-24 グリコド Ｇｄｐ−フコースを産生可能な酵母組換え細胞
SI2691417T2 (sl) 2011-03-29 2025-05-30 Roche Glycart Ag FC variante protitelesa
CN103596983B (zh) 2011-04-07 2016-10-26 霍夫曼-拉罗奇有限公司 抗fgfr4抗体及使用方法
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012144208A1 (ja) 2011-04-18 2012-10-26 国立大学法人東京大学 抗itm2a抗体を用いる癌の診断および治療
AU2012245491C1 (en) 2011-04-19 2017-12-21 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
PH12013502201A1 (en) 2011-04-25 2014-01-13 Daiichi Sankyo Co Ltd Anti-b7-h3 antibody
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
ES2657862T3 (es) 2011-05-13 2018-03-07 Gamamabs Pharma Anticuerpos contra HER3
ES2628385T3 (es) 2011-05-16 2017-08-02 F. Hoffmann-La Roche Ag Agonistas de FGFR1 y procedimientos de uso
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
EA036545B1 (ru) 2011-05-25 2020-11-20 Иннейт Фарма, С.А. Анти-kir антитела для лечения воспалительных заболеваний
PE20141045A1 (es) 2011-05-27 2014-09-10 Glaxo Group Ltd Proteinas de union a bcma (cd269/tnfrsf17)
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
RU2013158627A (ru) 2011-06-15 2015-07-20 Ф. Хоффманн-Ля Рош Аг Антитела к рецептору человеческого эритропоэтина и способы их применения
BR112013031762A2 (pt) 2011-06-16 2016-09-13 Novartis Ag proteínas solúveis para utilização como terapêuticos
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
KR20140033152A (ko) 2011-06-20 2014-03-17 교와 핫꼬 기린 가부시키가이샤 항erbB3 항체
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
EP2723376B1 (en) 2011-06-22 2018-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2723377B1 (en) 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
AU2012274127B2 (en) 2011-06-22 2017-06-22 F. Hoffmann-La Roche Ag Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes
PT2726094T (pt) 2011-06-28 2017-02-10 Oxford Biotherapeutics Ltd Alvo terapêutico e de diagnóstico
ES2640960T3 (es) 2011-06-28 2017-11-07 Oxford Biotherapeutics Ltd. Anticuerpos para ADP-ribosil ciclasa 2
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
WO2013006437A1 (en) 2011-07-01 2013-01-10 Novartis Ag Method for treating metabolic disorders
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN103857411A (zh) 2011-07-13 2014-06-11 阿布维公司 使用抗il-13抗体治疗哮喘的方法和组合物
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9499612B2 (en) 2011-07-27 2016-11-22 Glaxo Group Limited Antigen binding constructs
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
CN103890008A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 在顽固性肿瘤中抑制血管发生
CA2842375A1 (en) 2011-08-17 2013-02-21 Erica Jackson Neuregulin antibodies and uses thereof
RU2650775C2 (ru) 2011-08-23 2018-04-17 Рош Гликарт Аг Биспецифические антигенсвязывающие молекулы
KR20140048292A (ko) 2011-08-23 2014-04-23 로슈 글리카트 아게 항-mcsp 항체
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CN103930781A (zh) 2011-09-15 2014-07-16 霍夫曼-拉罗奇有限公司 促进分化的方法
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
CA2845147A1 (en) 2011-09-23 2013-03-28 Roche Glycart Ag Bispecific anti-egfr/anti igf-1r antibodies
EP2752200B1 (en) 2011-09-30 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
MX355877B (es) 2011-09-30 2018-05-03 Dana Farber Cancer Inst Inc Peptidos terapeuticos.
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
DK2766392T3 (da) 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP3653222A1 (en) 2011-10-14 2020-05-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
CA2850032C (en) 2011-10-14 2022-06-07 Genentech, Inc. Anti-htra1 antibodies and methods of use
BR112014008590A2 (pt) 2011-10-15 2017-10-24 Genentech Inc métodos de uso de antagonistas de scd1
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
CN104203978A (zh) 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
JP6251682B2 (ja) 2011-10-28 2017-12-20 ジェネンテック， インコーポレイテッド メラノーマ治療の治療の組み合わせ及び方法
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067054A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP2776061B1 (en) 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
CN104066748A (zh) 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
WO2013087789A1 (en) 2011-12-13 2013-06-20 Glykos Finland Ltd. Antibody isoform arrays and methods thereof
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
AP2014007761A0 (en) 2011-12-21 2014-07-31 Novartis Ag Compositions and methods for antibodies targeting factor P
BR112014013035A2 (pt) 2011-12-22 2018-10-09 Hoffmann La Roche métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
RU2756106C2 (ru) 2011-12-22 2021-09-28 Ф. Хоффманн-Ля Рош Аг Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
US20160208284A1 (en) 2011-12-22 2016-07-21 Hoffmann-La Roche Inc. Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
JP6684490B2 (ja) 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート 超長相補性決定領域及びその使用
CA2862979A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
PE20141561A1 (es) 2012-01-18 2014-11-12 Genentech Inc Anticuerpos anti-lrp5 y metodos de uso
MX2014008699A (es) 2012-01-18 2014-11-21 Genentech Inc Metodos para utilizar moduladores de fgf19.
EP2807192B1 (en) 2012-01-27 2018-04-18 Abbvie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
CN104244977A (zh) 2012-02-07 2014-12-24 先天制药公司 Mica结合剂
EP4624490A3 (en) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
CN104105711B (zh) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 单链抗体及其他异多聚体
WO2013120056A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
WO2013120929A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
CA2865082A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
WO2013147212A1 (ja) 2012-03-30 2013-10-03 第一三共株式会社 新規抗Ｓｉｇｌｅｃ－１５抗体
SG11201405966PA (en) 2012-03-30 2014-11-27 Daiichi Sankyo Co Ltd Cdr-modified anti-siglec-15 antibody
TWI669313B (zh) 2012-04-09 2019-08-21 第一三共股份有限公司 抗ＦＧＦＲ２抗體及其製造方法、及檢測或測定人類ＦＧＦＲ２ＩＩＩｂ之方法
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013160879A1 (en) 2012-04-27 2013-10-31 Daiichi Sankyo Company, Limited Anti-robo4-antibody
RU2014148162A (ru) 2012-05-01 2016-06-20 Дженентек, Инк. Анти-pmel17 антитела и их иммуноконъюгаты
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
KR101843614B1 (ko) 2012-05-23 2018-03-29 제넨테크, 인크. 치료제의 선택 방법
DK2852610T3 (en) 2012-05-23 2018-09-03 Glykos Finland Oy PRODUCTION OF FUCOSYLED GLYCOPROTEIN
EP2855531A1 (en) 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Multispecific antibodies
US20150166654A1 (en) 2012-05-30 2015-06-18 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
EP2855520B1 (en) 2012-06-04 2018-09-26 Novartis AG Site-specific labeling methods and molecules produced thereby
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
BR112014032276A2 (pt) 2012-06-22 2017-11-28 King S College London construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios
KR20150023889A (ko) 2012-06-27 2015-03-05 에프. 호프만-라 로슈 아게 2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
BR112014030844A2 (pt) 2012-07-04 2019-10-15 Hoffmann La Roche anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
ES2600154T3 (es) 2012-07-04 2017-02-07 F. Hoffmann-La Roche Ag Anticuerpos antiteofilina y métodos de uso
CA2871112C (en) 2012-07-04 2020-05-12 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
EP3578660A1 (en) 2012-07-05 2019-12-11 F. Hoffmann-La Roche AG Expression and secretion system
CA2877848C (en) 2012-07-06 2021-11-02 St. Marianna University School Of Medicine Therapeutic method and medicament for htlv-1 associated myelopathy (ham)
BR112015000439A2 (pt) 2012-07-09 2017-12-19 Genentech Inc imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação
EP2869847B1 (en) 2012-07-09 2017-12-06 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
HK1209043A1 (en) 2012-07-09 2016-03-24 基因泰克公司 Immunoconjugates comprising anti-cd22 antibodies
US20140030280A1 (en) 2012-07-09 2014-01-30 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
KR20150036710A (ko) 2012-07-18 2015-04-07 글리코토페 게엠베하 낮은 푸코실화를 갖는 항-her2 항체를 이용한 신규한 치료적 처리
CN110256559B (zh) 2012-07-25 2023-05-26 塞尔德克斯医疗公司 抗kit抗体及其用途
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CA2872195A1 (en) 2012-08-07 2014-02-13 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
EP3552628A1 (en) 2012-09-07 2019-10-16 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
KR101942148B1 (ko) 2012-09-27 2019-01-24 추가이 세이야쿠 가부시키가이샤 Ｆｇｆｒ３ 융합 유전자 및 그것을 표적으로 하는 의약
EP2905290B1 (en) 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
KR102237639B1 (ko) 2012-10-11 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
UY35110A (es) 2012-11-01 2014-05-30 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
KR102152481B1 (ko) 2012-11-05 2020-09-04 젠야쿠코교가부시키가이샤 항체 또는 항체 조성물의 제조 방법
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
AU2013337264B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
AR093378A1 (es) 2012-11-08 2015-06-03 Hoffmann La Roche PROTEINAS LIGANTES DE ANTIGENO HER3 DE UNION A LA HORQUILLA b DE HER3
BR112015010817A8 (pt) 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
CA2893767C (en) 2012-12-05 2022-11-08 Novartis Ag Compositions and methods for antibodies targeting epo
JP6310397B2 (ja) 2012-12-06 2018-04-11 国立大学法人金沢大学 中皮腫の治療方法
EP2930240B1 (en) 2012-12-07 2018-08-01 Kyowa Hakko Kirin Co., Ltd. Anti-folr1 antibody
JP6461808B2 (ja) 2012-12-17 2019-01-30 ラボラトワール フランセ ドゥ フラクションマン エ デ バイオテクノロジーズＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 炎症および細菌感染症処置におけるモノクローナル抗体の使用
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
WO2014096015A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
EP3336104A1 (en) 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
EP2938637A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
KR20210096697A (ko) 2013-01-10 2021-08-05 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
AU2014207342C1 (en) 2013-01-18 2019-04-04 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
EP2948177A1 (en) 2013-01-22 2015-12-02 AbbVie Inc. Methods for optimizing domain stability of binding proteins
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
US10077315B2 (en) 2013-02-05 2018-09-18 Engmab Sàrl Bispecific antibodies against CD3 and BCMA
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
AP2015008584A0 (en) 2013-02-08 2015-07-31 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
SI2953976T1 (sl) 2013-02-08 2021-08-31 Novartis Ag Specifična mesta z modificiranje protiteles za izdelavo imunokonjugatov
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
DK2956482T3 (en) 2013-02-14 2017-10-16 Innate Pharma TREATMENT OF PERFECT T cell lymphoma
EP2958941B1 (en) 2013-02-20 2019-04-10 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
US9328134B2 (en) 2013-02-22 2016-05-03 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
CN104936987A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 抗mcsp抗体
HK1213180A1 (zh) 2013-03-06 2016-06-30 豪夫迈‧罗氏有限公司 治疗和预防癌症药物抗性的方法
US9458245B2 (en) 2013-03-06 2016-10-04 Merrimack Pharmaceuticals, Inc. ANTI-C-MET tandem Fc bispecific antibodies
EP2975054A4 (en) 2013-03-12 2016-11-23 Zenyaku Kogyo Kk ANTIBODIES TO STAPHYLOKOKEN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
JP2016515132A (ja) 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
AU2014244424A1 (en) 2013-03-14 2015-08-27 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
US9194873B2 (en) 2013-03-14 2015-11-24 Abbott Laboratories HCV antigen-antibody combination assay and methods and compositions for use therein
WO2014143343A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
RS57393B1 (sr) 2013-03-15 2018-09-28 Hoffmann La Roche Il-22 polipeptiidi i il-22 fuzioni proteini i metode za njihovu upotrebu
EP2970452A2 (en) 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
KR20150131269A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
KR20150131173A (ko) 2013-03-15 2015-11-24 노파르티스 아게 항체 약물 접합체
RU2015143437A (ru) 2013-03-15 2017-04-27 Дженентек, Инк. Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
SI2970464T1 (sl) 2013-03-15 2020-08-31 Glaxosmithkline Intellectual Propety Development Limited Anti-LAG-3 vezavni proteini
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
MX2015012326A (es) 2013-03-15 2016-03-08 Genentech Inc Anticuerpos anti-crth2 y su uso.
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
WO2014145806A2 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins
US10745483B2 (en) 2013-03-15 2020-08-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
MX2015014773A (es) 2013-04-22 2016-03-04 Glycotope Gmbh Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.
SG11201508910WA (en) 2013-04-29 2015-11-27 Hoffmann La Roche Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
JP2016528167A (ja) 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒトＦｃＲｎ結合改変抗体及び使用方法
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
IL242088B2 (en) 2013-05-20 2023-12-01 Genentech Inc Anti-transferrin receptor antibodies and methods of use
BR112015029838A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus
BR112015029754A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos anti-teicoico da parede e conjugados
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
MX2015017852A (es) 2013-06-24 2016-08-11 Chugai Pharmaceutical Co Ltd Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma.
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
ME03476B (me) 2013-08-01 2020-01-20 Five Prime Therapeutics Inc Nefukozilisana anti-fgfr2iiib antitijela
US9862774B2 (en) 2013-08-09 2018-01-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PL3033104T3 (pl) 2013-08-12 2019-09-30 Astrazeneca Ab Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu
CA2918050C (en) 2013-08-12 2023-10-03 Medimmune, Llc Methods for improving asthma symptoms using benralizumab
PL3033101T3 (pl) 2013-08-12 2019-06-28 Astrazeneca Ab Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabu
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
US20160200818A1 (en) 2013-08-14 2016-07-14 Novartis Ag Methods of treating Sporadic Inclusion Body Myositis
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
KR20160055252A (ko) 2013-09-17 2016-05-17 제넨테크, 인크. 항-lgr5 항체의 사용 방법
TW201602341A (zh) 2013-09-30 2016-01-16 第一三共股份有限公司 抗ｌｐｓ ｏ１１抗體
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
RS60938B1 (sr) 2013-10-02 2020-11-30 Medimmune Llc Neutrališuća antitela na grip a i njihova upotreba
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
KR20160066024A (ko) 2013-10-08 2016-06-09 다이이찌 산쿄 가부시키가이샤 항 fgfr2 항체와 타제의 조합
UA119047C2 (uk) 2013-10-11 2019-04-25 Берлін-Хемі Аг Кон'юговане антитіло до ly75 для лікування раку
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
BR112016007635A2 (pt) 2013-10-11 2017-09-12 Genentech Inc inibidores de nsp4 e métodos de uso
ES2960807T3 (es) 2013-10-11 2024-03-06 Us Health Anticuerpos contra TEM8 y su uso
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015058132A2 (en) 2013-10-18 2015-04-23 Genentech, Inc. Anti-rspo antibodies and methods of use
BR112016008694A2 (pt) 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
BR112016010336A2 (pt) 2013-11-07 2017-10-03 Inst Nat Sante Rech Med Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
SI3071597T1 (sl) 2013-11-21 2020-11-30 F. Hoffmann-La Roche Ag Anti alfa-sinukleinska protitelesa in postopki uporabe
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
CN105980557B (zh) 2013-12-04 2020-04-07 中外制药株式会社 抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
US10106611B2 (en) 2013-12-06 2018-10-23 Dana-Farber Cancer Institute, Inc. Antibodies that bind to MHC class I polypeptide-related sequence A
HRP20192052T1 (hr) 2013-12-09 2020-02-07 Allakos Inc. Protutijela anti-siglec-8 te njihovi postupci i uporabe
EP3461845B1 (en) 2013-12-13 2020-09-16 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
BR112016013963A2 (pt) 2013-12-17 2017-10-10 Genentech Inc terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
FI3083686T4 (fi) 2013-12-17 2023-05-09 Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CA2933881A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
EP4566623A3 (en) 2013-12-20 2025-08-20 Intervet International B.V. Caninized antibodies
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
AU2014372309C1 (en) 2013-12-24 2017-12-14 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
IL320281A (en) 2013-12-25 2025-06-01 Daiichi Sankyo Co Ltd Anti-trop2 antibodies and methods for producing same
FI3088517T3 (fi) 2013-12-26 2023-11-30 Mitsubishi Tanabe Pharma Corp Ihmisen Anti-IL-33 neutraloiva monoklonaalinen vasta-aine
ES2756175T3 (es) 2013-12-27 2020-04-27 Chugai Pharmaceutical Co Ltd Genes mutantes guardián de fgfr y fármacos que se dirigen a los mismos
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
EP3089758B1 (en) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
EP3089996B1 (en) 2014-01-03 2021-07-28 F. Hoffmann-La Roche AG Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
BR112016015589A2 (pt) 2014-01-06 2017-10-31 Hoffmann La Roche módulos de trânsito monovalentes para a barreira hematoencefálica
EP3835318B1 (en) 2014-01-15 2025-10-29 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
FR3016633B1 (fr) 2014-01-17 2018-04-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Immunoglobuline anti-toxine du charbon
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
AU2015209154A1 (en) 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-STEAP1 antibodies and immunoconjugates
PH12020552271A1 (en) 2014-01-31 2022-05-02 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods for its use
KR102476641B1 (ko) 2014-02-08 2022-12-09 제넨테크, 인크. 알츠하이머병의 치료 방법
EP3718563A1 (en) 2014-02-08 2020-10-07 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
CA2936565C (en) 2014-02-12 2020-08-11 Genentech, Inc. Anti-jagged1 antibodies and methods of use
MX2016010729A (es) 2014-02-21 2016-10-26 Genentech Inc Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
TWI558399B (zh) 2014-02-26 2016-11-21 美國禮來大藥廠 癌症之組合療法
WO2015131155A1 (en) 2014-02-28 2015-09-03 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
CA2941697A1 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for modifying the immune response
WO2015138615A2 (en) 2014-03-12 2015-09-17 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
WO2015139046A1 (en) 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
JP2017510631A (ja) 2014-03-14 2017-04-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 癌に対しｎｋｇ２ｄ経路機能を回復させるためのワクチン組成物および方法
SG11201606789SA (en) 2014-03-14 2016-09-29 Innate Pharma Humanized antibodies with increased stability
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
JP2017511376A (ja) 2014-03-21 2017-04-20 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート
BR112016023417A2 (pt) 2014-03-21 2019-04-16 F. Hoffmann-La Roche Ag predição in vitro de meia-vida in vivo
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
EP3122781B1 (en) 2014-03-28 2020-01-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
JP6588461B2 (ja) 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
PE20161571A1 (es) 2014-03-31 2017-02-07 Genentech Inc Anticuerpos anti-ox40 y metodos de uso
KR101660580B1 (ko) * 2014-04-02 2016-09-28 프레스티지 바이오파마 피티이. 엘티디. 항체의 당 함량 조절을 통한 항체의 제조 방법
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
DK3129063T3 (da) 2014-04-10 2021-04-06 Daiichi Sankyo Co Ltd Anti-her3-antistof-lægemiddelkonjugat
HK1232127A1 (zh) 2014-04-11 2018-01-05 Medimmune, Llc 双特异性her2抗体
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
CN113933504A (zh) 2014-05-08 2022-01-14 中外制药株式会社 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
EP3145952A2 (en) 2014-05-22 2017-03-29 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
AU2015266664B2 (en) 2014-05-30 2020-04-30 Shanghai Henlius Biotech, Inc. Anti-epidermal growth factor receptor (EGFR) antibodies
EP3154584B1 (en) 2014-06-03 2021-08-04 XBiotech Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
CA2951234C (en) 2014-06-06 2022-05-31 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MX2016016233A (es) 2014-06-11 2017-03-31 Genentech Inc Anticuerpos anti-lgr5 y sus usos.
MX389695B (es) 2014-06-11 2025-03-20 Kathy A Green Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
CA2947504A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
AU2015279316B2 (en) 2014-06-27 2021-03-04 Innate Pharma Multispecific NKp46 binding proteins
JP6702893B2 (ja) 2014-06-27 2020-06-03 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的抗原結合タンパク質
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
SG11201700446XA (en) 2014-07-21 2017-02-27 Glykos Finland Oy Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
AU2015292326A1 (en) 2014-07-24 2017-02-23 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
MA40512A (fr) 2014-08-07 2021-03-24 Novartis Ag Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
TW201609099A (zh) 2014-08-11 2016-03-16 艾森塔製藥公司 使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
SMT202200285T1 (it) 2014-08-11 2022-09-14 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1
US9982045B2 (en) 2014-08-12 2018-05-29 Novartis Ag Anti-CDH6 antibody drug conjugates
JO3664B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme أجسام مضادة لـ tigit
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
RU2764074C2 (ru) 2014-08-28 2022-01-13 Байоатла, Ллк Условно активные химерные антигенные рецепторы для модифицированных т-клеток
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
KR102508173B1 (ko) 2014-09-12 2023-03-10 제넨테크, 인크. 항-her2 항체 및 면역콘주게이트
US9751946B2 (en) 2014-09-12 2017-09-05 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
HK1243629A1 (zh) 2014-09-17 2018-07-20 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CA2963470A1 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN107074938A (zh) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
EP3659625A1 (en) 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2016070001A1 (en) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
CA2966523A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
SG11201703521UA (en) 2014-11-03 2017-05-30 Genentech Inc Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
KR20170080675A (ko) 2014-11-05 2017-07-10 제넨테크, 인크. 항-fgfr2/3 항체 및 이의 이용 방법
HUE045466T2 (hu) 2014-11-06 2019-12-30 Hoffmann La Roche Fc-régió-variánsok módosított FcRn-kötéssel és alkalmazási eljárások
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
KR20170076697A (ko) 2014-11-06 2017-07-04 에프. 호프만-라 로슈 아게 개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체
MX2017006094A (es) 2014-11-10 2017-07-19 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos.
EP3552488A1 (en) 2014-11-10 2019-10-16 F. Hoffmann-La Roche AG Animal model for nephropathy and agents for treating the same
WO2016075670A1 (en) 2014-11-14 2016-05-19 Novartis Ag Antibody drug conjugates
EP3875481B1 (en) 2014-11-14 2025-01-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
PT3221359T (pt) 2014-11-17 2020-06-23 Regeneron Pharma Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20
EP3221360A1 (en) 2014-11-17 2017-09-27 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN107108745B (zh) 2014-11-19 2021-01-12 基因泰克公司 抗bace1的抗体和其用于神经疾病免疫疗法的用途
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
DK4141032T3 (da) 2014-11-20 2024-08-05 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
LT3221346T (lt) 2014-11-21 2020-11-10 Bristol-Myers Squibb Company Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
KR20230125855A (ko) 2014-11-21 2023-08-29 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
CN107206102A (zh) 2014-12-03 2017-09-26 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
EP3226908A1 (en) 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
SG11201704449VA (en) 2014-12-05 2017-06-29 Genentech Inc ANTI-CD79b ANTIBODIES AND METHODS OF USE
CN107405398A (zh) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
EP3230317A2 (en) 2014-12-10 2017-10-18 F. Hoffmann-La Roche AG Blood brain barrier receptor antibodies and methods of use
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016091268A2 (en) 2014-12-12 2016-06-16 University Of Copenhagen N-glycosylation
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
EP3233912B1 (en) 2014-12-19 2021-05-19 Regenesance B.V. Antibodies that bind human c6 and uses thereof
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
CN110256558B (zh) 2014-12-23 2023-07-04 百时美施贵宝公司 针对tigit的抗体
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
MX2017009254A (es) 2015-01-16 2017-10-12 Juno Therapeutics Inc Anticuerpos y receptores de antigeno quimerico especificos para ror1.
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
US10988534B2 (en) 2015-02-09 2021-04-27 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
US10227408B2 (en) 2015-02-19 2019-03-12 Compugen Ltd. Anti-PVRIG antibodies and methods of use
EP3978929A1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CA2977285A1 (en) 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
PT3271389T (pt) 2015-03-20 2020-05-13 Us Health Anticorpos neutralizantes dirigidos contra a gp120 e sua utilização
EP3072957B1 (en) 2015-03-23 2019-07-10 Lonza Ltd Methods for controlling protein glycosylation
AU2016235362B2 (en) 2015-03-23 2021-12-16 Jounce Therapeutics, Inc. Antibodies to ICOS
US10472412B2 (en) 2015-03-25 2019-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific multivalent fusion proteins
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
CN107683291B (zh) 2015-04-02 2021-11-19 英特维特国际股份有限公司 针对犬白介素-4受体α的抗体
RU2021124437A (ru) 2015-04-03 2021-09-29 Еурека Терапьютикс, Инк. Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
KR102886159B1 (ko) 2015-04-14 2025-11-13 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
CN115932273A (zh) 2015-04-24 2023-04-07 豪夫迈·罗氏有限公司 鉴定包含结合多肽的细菌的方法
CR20170539A (es) 2015-04-28 2018-04-20 Univ Osaka PROTEINA DE UNIÓN A RGma Y SU USO
CN107709363A (zh) 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
EP4238994A3 (en) 2015-05-11 2024-02-07 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
RS61152B2 (sr) 2015-05-12 2024-06-28 Hoffmann La Roche Terapeutski i dijagnostički postupci za lečenje raka
US11267899B2 (en) * 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
US10526415B2 (en) 2015-05-22 2020-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor
WO2016196343A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Humanized anti-ebola virus glycoprotein antibodies and methods of use
UY36692A (es) 2015-05-29 2016-12-30 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
HK1248773A1 (zh) 2015-05-29 2018-10-19 豪夫迈‧罗氏有限公司 用於癌症的治疗和诊断方法
AU2016271142A1 (en) 2015-05-29 2017-11-23 Genentech, Inc. PD-L1 promoter methylation in cancer
JP2018516933A (ja) 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
AU2016273028B2 (en) 2015-06-05 2019-02-14 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
JP2018518483A (ja) 2015-06-08 2018-07-12 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
JP2018521019A (ja) 2015-06-08 2018-08-02 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体を使用して癌を治療する方法
IL281396B (en) 2015-06-09 2022-07-01 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
JP2018524295A (ja) 2015-06-15 2018-08-30 ジェネンテック， インコーポレイテッド 抗体及び免疫複合体
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN107849132B (zh) 2015-06-16 2022-03-08 豪夫迈·罗氏有限公司 人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
EP3310378B1 (en) 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1 antibodies and methods of use
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
IL256080B2 (en) 2015-06-17 2025-06-01 Genentech Inc Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
WO2016205567A1 (en) 2015-06-17 2016-12-22 Allakos Inc. Methods and compositions for treating fibrotic diseases
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
JP2018524312A (ja) 2015-06-17 2018-08-30 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体及び使用方法
EP3313881A1 (en) 2015-06-23 2018-05-02 Innate Pharma Multispecific nk engager proteins
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
UA123053C2 (uk) 2015-06-24 2021-02-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
EP3313890A1 (en) 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3514174B1 (en) 2015-06-29 2021-03-31 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
CA2989936A1 (en) 2015-06-29 2017-01-05 Genentech, Inc. Type ii anti-cd20 antibody for use in organ transplantation
US11173213B2 (en) 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
DK3322733T3 (da) 2015-07-13 2021-10-18 Compugen Ltd Hide1-sammensætninger og fremgangsmåder
WO2017011517A1 (en) 2015-07-16 2017-01-19 Emory University Bis-amines, compositions, and uses related to cxcr4 inhibition
CA2994516A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
EP3932953A1 (en) 2015-08-28 2022-01-05 F. Hoffmann-La Roche AG Anti-hypusine antibodies and uses thereof
PT3344654T (pt) 2015-09-02 2021-01-26 Immutep Sas Anticorpos anti-lag-3
EP3347377B1 (en) 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
MY203894A (en) 2015-09-18 2024-07-23 Chugai Pharmaceutical Co Ltd Il-8-binding antibodies and uses thereof
JP6904947B2 (ja) 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション 抗ｏｘ４０抗体及びその診断用途
KR102725051B1 (ko) 2015-09-23 2024-11-04 제넨테크, 인크. 항-vegf 항체의 최적화된 변이체들
CN110922481A (zh) 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
CN108289954B (zh) 2015-09-24 2022-05-31 阿布维特罗有限责任公司 Hiv抗体组合物和使用方法
KR20230125094A (ko) 2015-09-25 2023-08-28 제넨테크, 인크. 항-tigit 항체 및 이의 이용 방법
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
MA43023A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
HUE069935T2 (hu) 2015-10-06 2025-04-28 Hoffmann La Roche Módszer szklerózis multiplex kezelésére
WO2017062748A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
KR20180066236A (ko) 2015-10-22 2018-06-18 조운스 테라퓨틱스, 인크. Icos 발현을 계측하기 위한 유전자 특질
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
JP6949016B2 (ja) 2015-10-29 2021-10-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗バリアントＦｃ領域抗体および使用法
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
RU2750285C2 (ru) 2015-10-30 2021-06-25 Дженентек, Инк. АНТИТЕЛА ПРОТИВ НtrА1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2017079479A1 (en) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Neutralizing antibodies to hiv-1 gp41 and their use
CN108602884B (zh) 2015-11-08 2024-06-25 豪夫迈·罗氏有限公司 筛选多特异性抗体的方法
BR112018010085A2 (pt) 2015-11-18 2018-11-13 Merck Sharp & Dohme ligantes de pd1/ctla4
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
KR20250034528A (ko) 2015-11-23 2025-03-11 파이브 프라임 테라퓨틱스, 인크. 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
UY37003A (es) 2015-12-04 2017-06-30 Novartis Ag Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
WO2017100372A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
KR102850929B1 (ko) 2015-12-09 2025-08-27 에프. 호프만-라 로슈 아게 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
EP4541807A3 (en) 2015-12-18 2025-09-24 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
CA3002422C (en) 2015-12-18 2024-04-16 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
IL259256B2 (en) 2015-12-18 2023-02-01 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
CA3008102A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
PL3402503T3 (pl) 2016-01-13 2021-04-19 Acerta Pharma B.V. Kombinacje terapeutyczne antyfolianu oraz inhibitora btk
CN114019170A (zh) 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
RU2767329C2 (ru) 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
TWI756204B (zh) 2016-02-12 2022-03-01 比利時商楊森製藥公司 抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
US11180546B2 (en) 2016-02-17 2021-11-23 Novartis Ag TGFbeta 2 antibodies
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
EP3423491A1 (en) 2016-03-01 2019-01-09 H. Hoffnabb-La Roche Ag Obinutuzumab variants having altered cell death induction
KR20220033522A (ko) 2016-03-04 2022-03-16 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
EP3430054B1 (en) 2016-03-15 2021-12-29 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
KR20180118673A (ko) 2016-03-15 2018-10-31 이나뜨 파르마 항-mica 항체
KR20180138205A (ko) 2016-03-22 2018-12-28 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
KR102640157B1 (ko) 2016-03-22 2024-02-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 인간화 항-클라우딘-1 항체 및 이의 용도
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
WO2017181034A1 (en) 2016-04-14 2017-10-19 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
US20170319688A1 (en) 2016-04-14 2017-11-09 Genentech, Inc. Anti-rspo3 antibodies and methods of use
BR112018071153A2 (pt) 2016-04-15 2019-04-16 Immunext, Inc. anticorpos anti-vista humano e uso dos mesmos
JP7503887B2 (ja) 2016-04-15 2024-06-21 ジェネンテック， インコーポレイテッド がんを監視及び治療するための方法
CN109563164A (zh) 2016-04-15 2019-04-02 生物蛋白有限公司 抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
CA3020718A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
EP3445393A4 (en) 2016-04-20 2020-08-05 Merck Sharp & Dohme Corp. CMV NEUTRALIZATION ANTIGEN BINDING PROTEINS
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
CR20180509A (es) 2016-05-02 2019-02-15 Hoffmann La Roche Contorsbody - un ligante de diana monocatenario
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
JP7089483B2 (ja) 2016-05-11 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 修飾された抗テネイシン抗体及び使用方法
TWI844509B (zh) 2016-05-13 2024-06-11 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
WO2017198731A1 (en) 2016-05-18 2017-11-23 Genmab B.V. Antibodies and methods of use thereof in treatment of infectious disease
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
TW201806626A (zh) 2016-06-08 2018-03-01 美商艾伯維有限公司 抗egfr抗體藥物結合物
FI3468997T3 (fi) 2016-06-08 2023-10-31 Xencor Inc Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een
UY37278A (es) 2016-06-08 2018-01-31 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
AU2017277920A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
CA3027181A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
US20200002432A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3468615A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-egfr antibody drug conjugates
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
AU2017277916A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
JP7231411B2 (ja) 2016-06-15 2023-03-01 ノバルティス アーゲー 骨形成タンパク質６（ｂｍｐ６）の阻害剤を使用して疾患を処置する方法
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
KR102376582B1 (ko) 2016-06-17 2022-03-18 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
WO2017223405A1 (en) 2016-06-24 2017-12-28 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
SG10201911972QA (en) 2016-07-14 2020-02-27 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
JP7316930B2 (ja) 2016-07-15 2023-07-28 武田薬品工業株式会社 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
KR20230107408A (ko) 2016-07-29 2023-07-14 주노 쎄러퓨티크스 인코퍼레이티드 항-cd19 항체에 대한 항-이디오타입 항체
CN109415444B (zh) 2016-07-29 2024-03-01 中外制药株式会社 显示增加的备选fviii辅因子功能活性的双特异性抗体
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
ES3041722T3 (en) 2016-07-29 2025-11-14 Inst Nat Sante Rech Med Antibodies targeting tumor associated macrophages and uses thereof
EP3490676A1 (en) 2016-07-29 2019-06-05 Eli Lilly and Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
EP3494142A4 (en) 2016-08-05 2020-04-01 Allakos, Inc. ANTI-SIGLEC-7 ANTIBODIES FOR THE TREATMENT OF CANCER
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
CA3032430A1 (en) 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
EP3510046A4 (en) 2016-09-07 2020-05-06 The Regents of the University of California ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
EP3512883A1 (en) 2016-09-13 2019-07-24 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN116731197A (zh) 2016-09-19 2023-09-12 豪夫迈·罗氏有限公司 基于补体因子的亲和层析
HRP20231015T1 (hr) 2016-09-23 2023-12-08 F. Hoffmann-La Roche Ag Upotreba antagonista il-13 u liječenju atopičnog dermatitisa
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
KR20190062505A (ko) 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
MX2019003934A (es) 2016-10-06 2019-07-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
CA3036941C (en) 2016-10-07 2023-02-21 Daiichi Sankyo Company, Limited Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CR20190193A (es) 2016-10-13 2019-08-21 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
MA46534A (fr) 2016-10-14 2019-08-21 Xencor Inc Protéines de fusion fc hétérodimères il15/il15r
KR20230173745A (ko) 2016-10-21 2023-12-27 이나뜨 파르마 에스.에이. 항-kir3dl2 작용제에 의한 치료
KR20190084264A (ko) 2016-10-25 2019-07-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cd160 막 횡단 동형체에 결합하는 단클론 항체
KR20190075921A (ko) 2016-10-28 2019-07-01 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US20190263926A1 (en) 2016-10-28 2019-08-29 Astute Medical, Inc. Use of Antibodies to TIMP-2 for the Improvement of Renal Function
JP2019535250A (ja) 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR20190070977A (ko) 2016-11-01 2019-06-21 젠맵 비. 브이 폴리펩티드 변이체 및 그의 용도
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
CN110392694B (zh) 2016-11-02 2023-08-04 震动疗法股份有限公司 针对pd-1的抗体及其用途
MY200695A (en) 2016-11-03 2024-01-11 Bristol Myers Squibb Co Activatable anti-ctla-4 antibodies and uses thereof
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
CN109923128A (zh) 2016-11-15 2019-06-21 基因泰克公司 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
ES2866348T3 (es) 2016-11-16 2021-10-19 Lilly Co Eli Terapia de combinación para el cáncer con mutación o mutaciones de omisión del exón 14 o fenotipo de omisión del exón 14
WO2018091724A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
MX2019005772A (es) 2016-11-23 2019-10-02 Bioverativ Therapeutics Inc Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
JP7274417B2 (ja) 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド ４－１ｂｂ結合タンパク質及びその使用
WO2018101448A1 (en) 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
CN110049779A (zh) 2016-12-12 2019-07-23 第一三共株式会社 抗体-药物缀合物和免疫检查点抑制剂的组合
EP3551663A1 (en) 2016-12-12 2019-10-16 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
CN110234348B (zh) 2016-12-16 2024-06-25 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
IL267567B2 (en) 2016-12-22 2024-08-01 Daiichi Sankyo Co Ltd Anti-cd3 antibody for use in the treatment or prophylaxis of cancer, and molecules containing said antibody
US20190322767A1 (en) 2016-12-23 2019-10-24 Innate Pharma Heterodimeric antigen binding proteins
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
SG11201903021WA (en) 2017-01-06 2019-05-30 Eutilex Co Ltd Anti-human 4-1 bb antibodies and use thereof
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
CA3049163A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
TW201831517A (zh) 2017-01-12 2018-09-01 美商優瑞科生物技術公司 靶向組織蛋白h3肽/mhc複合體之構築體及其用途
EP3572428A4 (en) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
EP3574918B1 (en) 2017-01-24 2025-10-15 Kyowa Kirin Co., Ltd. Therapeutic or prophylactic agent for treating radiation damage
SG11201907321TA (en) 2017-02-07 2019-09-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
KR102572663B1 (ko) 2017-02-08 2023-09-01 노파르티스 아게 Fgf21 모방 항체 및 이의 용도
EP3882271A3 (en) 2017-02-10 2022-01-05 Eutilex Co., Ltd. Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
TWI778018B (zh) 2017-02-10 2022-09-21 美商建南德克公司 抗類胰蛋白酶抗體、其組合物及其用途
KR20250140128A (ko) 2017-02-10 2025-09-24 젠맵 비. 브이 폴리펩티드 변이체 및 그의 용도
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
EP3580235B1 (en) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JP2020509037A (ja) 2017-02-28 2020-03-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ワクチンに対する免疫応答を増強するための、ａｄｃｃが増強された抗ｃｔｌａ−４抗体の使用
CA3053749A1 (en) 2017-02-28 2018-09-07 Kinki University Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
ES2953595T3 (es) 2017-03-01 2023-11-14 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
US20200010553A1 (en) 2017-03-02 2020-01-09 St. Marianna University School Of Medicine Preventive or therapeutic agent for htlv-1 associated myelopathy using low-dose of anti-ccr4 antibody
AR111249A1 (es) 2017-03-22 2019-06-19 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
IL269083B2 (en) 2017-03-24 2024-12-01 Novartis Ag Methods for preventing and treating heart disease
KR20190133162A (ko) 2017-03-28 2019-12-02 제넨테크, 인크. 신경퇴행성 질병의 치료 방법
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
JP2020516253A (ja) 2017-04-14 2020-06-11 ジェネンテック， インコーポレイテッド がんのための診断及び治療方法
US11932694B2 (en) 2017-04-19 2024-03-19 Bluefin Biomedicine, Inc. Anti-VTCN1 antibodies and antibody drug conjugates
JP7248588B2 (ja) 2017-04-21 2023-03-29 ジェネンテック， インコーポレイテッド 疾患の治療のためのｋｌｋ５アンタゴニストの使用
AU2018258049B2 (en) 2017-04-26 2025-03-27 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
KR102769634B1 (ko) 2017-04-27 2025-02-19 테사로, 인코포레이티드 림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EA201992626A1 (ru) 2017-05-05 2020-04-24 Аллакос Инк. Способы и композиции для лечения аллергических заболеваний глаз
EP3622055A1 (en) 2017-05-10 2020-03-18 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US11116835B2 (en) 2017-05-10 2021-09-14 Fred Hutchinson Cancer Research Center Epstein Barr virus antibodies, vaccines, and uses of the same
WO2018213097A1 (en) 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
TW202530271A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體－藥物結合物及其用途
PT3624837T (pt) 2017-05-16 2025-10-01 Five Prime Therapeutics Inc Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro
PE20251254A1 (es) 2017-05-24 2025-05-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
CN111107868A (zh) 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
CN110719915A (zh) 2017-05-25 2020-01-21 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
KR20250005551A (ko) 2017-05-29 2025-01-09 엑셀리시스, 인코포레이티드 암 연관 면역억제의 억제제
MX2019014265A (es) 2017-06-01 2020-08-03 Compugen Ltd Tratamientos conjuntos triples con anticuerpos.
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
TW201908341A (zh) 2017-07-18 2019-03-01 日商協和醱酵麒麟有限公司 抗人類ccr1單株抗體
IL271888B2 (en) 2017-07-21 2024-09-01 Genentech Inc Therapeutic and diagnostic methods for cancer
CN111448210B (zh) 2017-07-26 2024-05-14 四十七公司 抗SIRP-α抗体及相关方法
EP3660155A4 (en) 2017-07-27 2021-04-07 Daiichi Sankyo Company, Limited ANTI-CD147 ANTIBODY
EP3673918A4 (en) 2017-08-23 2021-05-19 Daiichi Sankyo Company, Limited PREPARATION OF AN ANTIBODY INGREDIENT CONJUGATE AND LYOPHILIZATION FOR IT
CA3070774A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
KR20250084239A (ko) 2017-08-31 2025-06-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
IL273202B2 (en) 2017-09-11 2024-08-01 Univ Monash Binding proteins to the human thrombin receptor, par4
US20200216542A1 (en) 2017-09-20 2020-07-09 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
JP7273716B2 (ja) 2017-09-29 2023-05-15 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
CN111447952A (zh) 2017-10-05 2020-07-24 第一三共株式会社 用于细胞毒性t细胞耗竭的组合物
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
CN111372950B (zh) 2017-10-12 2024-11-05 免疫苏醒公司 Vegfr-抗体轻链融合蛋白
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
CA3077664A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3708589A4 (en) 2017-11-08 2021-08-11 Kyowa Kirin Co., Ltd. BISPECIFIC ANTIBODIES THAT BIND TO CD40 AND EpCAM
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
EP4640703A2 (en) 2017-11-14 2025-10-29 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
US20200325232A1 (en) 2017-11-21 2020-10-15 Innate Pharma Multispecific antigen binding proteins
CN111902427A (zh) 2017-11-22 2020-11-06 诺华股份有限公司 抗因子XI/XIa抗体的逆转结合剂及其用途
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
US20210171598A1 (en) 2017-12-01 2021-06-10 University Of Copenhagen Peptide hormone with one or more o-glycans
US11433132B2 (en) 2017-12-01 2022-09-06 Novartis Ag Polyomavirus neutralizing antibodies
JP7391839B2 (ja) 2017-12-01 2023-12-05 ファイザー・インク 抗ｃｘｃｒ５抗体、その組成物及びその使用
CA3085765A1 (en) 2017-12-15 2019-06-20 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
CN112204048A (zh) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 抗cct5结合分子及其使用方法
MA51291A (fr) 2017-12-19 2020-10-28 Xencor Inc Protéines de fusion il-2 fc modifiées
CN111699196A (zh) 2017-12-22 2020-09-22 震动疗法公司 针对lilrb2的抗体
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN115925943A (zh) 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
JP7383617B2 (ja) 2017-12-28 2023-11-20 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｐｄ－ｌ１に対する抗体及びそのバリアント
EP3732196A4 (en) 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND ASSAYS FOR CCL14
JP7369127B2 (ja) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
WO2019136029A1 (en) 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
CA3086879A1 (en) 2018-01-05 2019-07-11 Ac Immune Sa Misfolded tdp-43 binding molecules
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN111886255B (zh) 2018-01-12 2025-04-04 百时美施贵宝公司 抗tim3抗体及其用途
KR20250114571A (ko) 2018-01-15 2025-07-29 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
WO2019143636A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
CA3088763A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Compositions and methods of use
AR114565A1 (es) 2018-01-26 2020-09-23 Genentech Inc Proteínas de fusión fc il-22 y métodos de uso
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
CA3081125C (en) 2018-02-01 2025-09-16 Innovent Biologics (Suzhou) Co., Ltd. All-Human Single-Chain Variable Fragment Anti-Antigen for B Lymphocyte Maturation (BCMA), and Associated Application
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
CN118772288A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
WO2019157358A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
US20210137930A1 (en) 2018-02-13 2021-05-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
CA3091646A1 (en) 2018-02-14 2019-08-22 Abba Therapeutics Ag Anti-human pd-l2 antibodies
EP3755720A1 (en) 2018-02-21 2020-12-30 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
RU2020128111A (ru) 2018-02-21 2022-03-21 Дженентек, Инк. ВЕДЕНИЕ БЕЛКОВ СЛИЯНИЯ IL-22 Fc ДЛЯ ЛЕЧЕНИЯ
WO2019165122A1 (en) 2018-02-21 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
MA51902A (fr) 2018-02-21 2021-05-26 Five Prime Therapeutics Inc Schémas posologiques d'anticorps b7-h4
CA3092108A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
AU2019228600A1 (en) 2018-03-02 2020-09-24 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
US11859006B2 (en) 2018-03-05 2024-01-02 Saitama Medical University Method of treating ectopic ossification or diffuse intrinsic pontine glioma in a subject by administering an anti-ALK2 antibody
TW202003562A (zh) 2018-03-14 2020-01-16 中國大陸商北京軒義醫藥科技有限公司 抗密連蛋白18.2(cldn18.2)抗體
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
TWI887899B (zh) 2018-03-15 2025-06-21 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體之用途
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
EP3777888A4 (en) 2018-03-30 2021-12-01 Toray Industries, Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
KR102764123B1 (ko) 2018-04-05 2025-02-05 주노 쎄러퓨티크스 인코퍼레이티드 Τ 세포 수용체 및 이를 발현하는 조작된 세포
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
AU2019264217A1 (en) 2018-05-03 2020-12-17 Genmab B.V. Antibody variant combinations and uses thereof
WO2019213384A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
CA3097916A1 (en) 2018-05-03 2019-11-07 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
SG11202011308VA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable cytokine polypeptides and methods of use thereof
JP7460609B2 (ja) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
US12479926B2 (en) 2018-05-18 2025-11-25 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
JP2021525243A (ja) 2018-05-21 2021-09-24 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Ｎｋ細胞による標的細胞の殺傷を増進するための組成物および方法
WO2019230645A1 (ja) 2018-05-28 2019-12-05 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート投与によるｈｅｒ２変異がんの治療
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
CA3099900A1 (en) 2018-05-31 2019-12-05 Daiichi Sankyo Company, Limited Anti-human tlr7 antibody
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
WO2019228514A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CN118459594A (zh) 2018-06-01 2024-08-09 诺华股份有限公司 针对bcma的结合分子及其用途
KR20210029158A (ko) 2018-06-03 2021-03-15 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이성 항체
EP3805400A4 (en) 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule showing changed half-life in cytoplasm
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
SG11202012342WA (en) 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
AU2019288728A1 (en) 2018-06-23 2021-01-14 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
CN112424358B (zh) 2018-06-26 2025-07-01 协和麒麟株式会社 与细胞粘附分子3结合的抗体
CA3104997A1 (en) 2018-06-26 2020-01-02 Kyowa Kirin Co., Ltd. Antibody binding to chondroitin sulfate proteoglycan 5
UY38289A (es) 2018-07-02 2020-01-31 Amgen Inc Proteína de unión al antígeno anti-steap1
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3820902A2 (en) 2018-07-11 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
JP7534281B2 (ja) 2018-07-13 2024-08-14 ジェンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
MY205398A (en) 2018-07-13 2024-10-19 Genmab As Variants of cd38 antibody and uses thereof
TW202011991A (zh) 2018-07-18 2020-04-01 美商建南德克公司 用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
MX2021000745A (es) 2018-07-20 2021-03-26 Surface Oncology Inc Composiciones anti-cd112r y metodos.
TWI865337B (zh) 2018-07-25 2024-12-01 日商第一三共股份有限公司 抗體-藥物結合物之有效的製造方法
US12220604B2 (en) 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
CN113286824A (zh) 2018-08-03 2021-08-20 中外制药株式会社 包含两个彼此连接的抗原结合结构域的抗原结合分子
KR20210042120A (ko) 2018-08-06 2021-04-16 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 튜불린 저해제의 조합
US12172106B2 (en) 2018-08-09 2024-12-24 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptor
MX2021001431A (es) 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
CN112584863B (zh) 2018-08-17 2025-10-28 Ab工作室有限公司 催化抗体和其使用方法
JP7481255B2 (ja) 2018-08-23 2024-05-10 第一三共株式会社 抗体薬物複合体の感受性マーカー
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
CN112673022B (zh) 2018-09-10 2024-07-09 南京传奇生物科技有限公司 针对cd33的单结构域抗体及其构建体
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
KR20210061341A (ko) 2018-09-13 2021-05-27 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 신규한 lilrb4 항체 및 이의 용도
CN112955747A (zh) 2018-09-19 2021-06-11 豪夫迈·罗氏有限公司 膀胱癌的治疗和诊断方法
US20220073638A1 (en) 2018-09-19 2022-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
US20220072144A1 (en) 2018-09-20 2022-03-10 Daiichi Sankyo Company, Limited Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate
KR20210064269A (ko) 2018-09-20 2021-06-02 이오반스 바이오테라퓨틱스, 인크. 동결보존된 종양 샘플로부터의 til의 확장
ES2955032T3 (es) 2018-09-21 2023-11-28 Hoffmann La Roche Métodos de diagnóstico para el cáncer de mama triple negativo
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
US20210380684A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Antibody composition
CA3115096A1 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
US20220010020A1 (en) 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
JP2022504839A (ja) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド 抗ｌａｐ抗体変異体及びその使用
CN113166242B (zh) 2018-10-15 2024-11-19 戊瑞治疗有限公司 用于癌症的组合疗法
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
AU2019361983A1 (en) 2018-10-18 2021-05-20 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
MX2021004775A (es) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
CA3118634A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
WO2020094609A1 (en) 2018-11-06 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
CN119735694A (zh) 2018-11-13 2025-04-01 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
KR20210091711A (ko) 2018-11-14 2021-07-22 다이이찌 산쿄 가부시키가이샤 항 cdh6 항체-피롤로벤조디아제핀 유도체 컨쥬게이트
EP4640698A2 (en) 2018-11-16 2025-10-29 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
CA3120729A1 (en) 2018-11-27 2020-06-04 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP4198057A1 (en) 2018-12-05 2023-06-21 F. Hoffmann-La Roche AG Diagnostic methods and compositions for cancer immunotherapy
WO2020117257A1 (en) 2018-12-06 2020-06-11 Genentech, Inc. Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
KR20210102341A (ko) 2018-12-11 2021-08-19 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 parp 저해제의 조합
EP3894543A1 (en) 2018-12-14 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
WO2020132214A2 (en) 2018-12-20 2020-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
WO2020132230A2 (en) 2018-12-20 2020-06-25 Genentech, Inc. Modified antibody fcs and methods of use
SG11202106100VA (en) 2018-12-21 2021-07-29 23Andme Inc Anti-il-36 antibodies and methods of use thereof
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
KR20210142594A (ko) 2018-12-26 2021-11-25 시티 오브 호프 활성화 가능한 차폐된 항-ctla4 결합 단백질
MX2021007797A (es) 2018-12-28 2021-10-26 Kyowa Kirin Co Ltd Anticuerpo biespecifico que se une al receptor de transferrina (tfr).
CN113272327A (zh) 2018-12-30 2021-08-17 豪夫迈·罗氏有限公司 抗兔cd19抗体及其使用方法
EP3908678A1 (en) 2019-01-10 2021-11-17 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
WO2020148207A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies binding to hla-a2
JP2022518399A (ja) 2019-01-14 2022-03-15 ジェネンテック， インコーポレイテッド Ｐｄ－１軸結合アンタゴニスト及びｒｎａワクチンを用いてがんを処置する方法
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN113396162B (zh) 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
WO2020152290A1 (en) 2019-01-23 2020-07-30 Encefa Cd31 competitors and uses thereof
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
JP2022521773A (ja) 2019-02-27 2022-04-12 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ抗体と抗ｃｄ２０抗体又は抗ｃｄ３８抗体とによる処置のための投薬
BR112021016875A2 (pt) 2019-03-01 2022-01-04 Iovance Biotherapeutics Inc Processo para expansão de linfócitos de sangue periférico
BR112021016955A2 (pt) 2019-03-01 2021-11-23 Xencor Inc Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
EP3935385A1 (en) 2019-03-08 2022-01-12 F. Hoffmann-La Roche AG Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
EP3938400B1 (en) 2019-03-11 2025-07-30 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
CR20210467A (es) 2019-03-14 2021-10-07 Genentech Inc Tratamiento de cáncer con anticuerpos biespecíficos contra her2xcd3 en combinación con mab anti-her2
CN121159688A (zh) 2019-03-19 2025-12-19 中外制药株式会社 包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
SG11202109860VA (en) 2019-03-25 2021-10-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
BR112021017350A2 (pt) 2019-03-27 2021-11-16 Daiichi Sankyo Co Ltd Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
CN113874392B (zh) 2019-03-28 2025-10-21 丹尼斯科美国公司 工程化抗体
KR20210153100A (ko) 2019-04-18 2021-12-16 브리스톨-마이어스 스큅 컴퍼니 낮은 pH에서의 결합에 대한 증진된 특이성을 갖는 이필리무맙 변이체
AU2020257748A1 (en) 2019-04-19 2021-11-18 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor recognizing modification site of antibody
BR112021020867A2 (pt) 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
KR20220004744A (ko) 2019-05-03 2022-01-11 제넨테크, 인크. 항-pd-l1 항체를 이용하여 암을 치료하는 방법
EP3962523A2 (en) 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
EP3968993A1 (en) 2019-05-14 2022-03-23 F. Hoffmann-La Roche AG Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
TWI875760B (zh) 2019-05-15 2025-03-11 日商協和麒麟股份有限公司 與cd40及gpc3結合之雙專一性抗體
KR20220008820A (ko) 2019-05-15 2022-01-21 쿄와 기린 가부시키가이샤 Cd40과 fap에 결합하는 이중 특이적 항체
JP2022533215A (ja) 2019-05-20 2022-07-21 ノバルティス アーゲー 親水性基を含むリンカーを有する抗体薬剤コンジュゲート
JP2022538733A (ja) 2019-05-20 2022-09-06 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 新規抗ｃｄ２５抗体
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
US20220396631A1 (en) 2019-05-21 2022-12-15 Lu HUANG Trispecific binding molecules against bcma and uses thereof
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
MX2021014274A (es) 2019-05-23 2022-01-06 Ac Immune Sa Moleculas de union anti-tdp-43 y usos de las mismas.
CA3142119A1 (en) 2019-05-29 2020-12-03 Daiichi Sankyo Company, Limited Dosage of an antibody-drug conjugate for treating cancer
CN119613549A (zh) 2019-06-12 2025-03-14 诺华股份有限公司 利钠肽受体1抗体及使用方法
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
JP2022539589A (ja) 2019-07-02 2022-09-12 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＥＧＦＲｖＩＩＩと結合するモノクローナル抗体およびその使用
AU2020311511B2 (en) 2019-07-09 2024-08-29 Beijing Solobio Genetechnology Co., Ltd. Antibodies specifically recognizing Pseudomonas PcrV and uses thereof
EP3998083A4 (en) 2019-07-12 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor
AU2020312686A1 (en) 2019-07-15 2022-02-03 Intervet International B.V. Caninized antibodies against canine CTLA-4
BR112022000604A2 (pt) 2019-07-15 2022-03-03 Intervet Int Bv Anticorpos caninizados para ctla-4 humana
US12319745B2 (en) 2019-07-16 2025-06-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for CD38 and uses thereof
BR112021005478A2 (pt) 2019-07-24 2021-06-15 H. Lundbeck A/S anticorpos anti-mglur5 e uso dos mesmos
US20220267453A1 (en) 2019-07-26 2022-08-25 Saitama Medical University Antibody recognizing extracellular region of alk2/acvr1
BR112022001575A2 (pt) 2019-07-29 2022-04-19 Compugen Ltd Formulações de anticorpos anti-pvrig e usos dos mesmos
TWI832183B (zh) 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
CN120204384A (zh) 2019-08-06 2025-06-27 葛兰素史密斯克莱知识产权发展有限公司 生物药物组合物和相关方法
JP7331298B2 (ja) 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合ｔｓｌｐ及びその使用
MX2022002963A (es) 2019-09-12 2022-04-06 Genentech Inc Composiciones y metodos para tratar nefritis lupica.
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
PE20220566A1 (es) 2019-09-19 2022-04-13 Bristol Myers Squibb Co ANTICUERPOS DE UNION A VISTA A pH ACIDO
US20220348687A1 (en) 2019-09-20 2022-11-03 Genentech, Inc. Dosing for anti-tryptase antibodies
TW202126688A (zh) 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
CR20220127A (es) 2019-09-27 2022-05-27 Genentech Inc Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
WO2021064184A1 (en) 2019-10-04 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
CA3153880A1 (en) 2019-10-18 2020-06-09 Juana Elva HERNANDEZ MONTALVO Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN114980922A (zh) 2019-11-04 2022-08-30 康姆普根有限公司 抗pvrig抗体制剂和抗pd-1抗体的组合疗法
US20220389103A1 (en) 2019-11-06 2022-12-08 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
EP4058593A4 (en) 2019-11-12 2023-11-15 Foundation Medicine, Inc. METHOD FOR DETECTING A FUSION GENE CODING A NEOANTIGEN
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
JP2023504740A (ja) 2019-12-06 2023-02-06 ジュノー セラピューティクス インコーポレイテッド Ｂｃｍａ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
US20230192869A1 (en) 2019-12-06 2023-06-22 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
EP4072682A1 (en) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity to her4 and uses thereof
KR20220113790A (ko) 2019-12-13 2022-08-16 제넨테크, 인크. 항-ly6g6d 항체 및 사용 방법
WO2021123094A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
KR20220116255A (ko) 2019-12-20 2022-08-22 브리스톨-마이어스 스큅 컴퍼니 비-푸코실화 항체의 제조를 위한 푸코실화 억제제의 용도
WO2021123091A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Canine interleukin-4 receptor alpha antibodies
AR120898A1 (es) 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
CN110964090B (zh) * 2019-12-26 2021-02-19 江南大学 一种促进n-乙酰氨基葡萄糖生产的蛋白质起始因子if3突变体及其应用
IL294226B2 (en) 2019-12-27 2025-05-01 Chugai Pharmaceutical Co Ltd Anti-CTLA-4 antibodies and their use
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
KR102837521B1 (ko) 2020-01-03 2025-07-22 바이오션, 인코포레이티드 Bcma에 결합하는 항체 및 이의 용도
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CA3168209A1 (en) 2020-01-15 2021-07-22 Osaka University Prophylactic or therapeutic agent for dementia
KR20220130724A (ko) 2020-01-16 2022-09-27 젠맵 에이/에스 Cd38 항체의 제제 및 그의 용도
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CA3165319A1 (en) 2020-01-31 2021-08-05 Vincent K. Tuohy Anti-mullerian hormone receptor 2 antibodies and methods of use
BR112022015077A2 (pt) 2020-01-31 2022-10-04 Genentech Inc Métodos para induzir células t cd8+ específicas de neoepítopos em um indivíduo com um tumor e para induzir o tráfico de células t cd8+, vacinas de rna, vacina de rna para uso e antagonistas de ligação
IL295387A (en) 2020-02-05 2022-10-01 Larimar Therapeutics Inc Tat peptide binding proteins and uses thereof
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
TWI888487B (zh) 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
US20230348568A1 (en) 2020-02-20 2023-11-02 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus monoclonal antibodies and uses thereof
WO2021170020A1 (en) 2020-02-27 2021-09-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
KR20220145859A (ko) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
CN115066440A (zh) 2020-02-28 2022-09-16 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
US20230139178A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2021182574A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
JP7765397B2 (ja) 2020-03-12 2025-11-06 イミューン－オーエヌシー セラピューティクス，インコーポレーテッド 新規抗ｌｉｌｒｂ４抗体および派生産物
EP4119156A4 (en) 2020-03-12 2024-05-08 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
CA3175129A1 (en) 2020-03-12 2021-09-19 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US11919948B2 (en) 2020-03-19 2024-03-05 Genentech, Inc. Isoform-selective anti-TGFβ antibodies and methods of use
PE20230821A1 (es) 2020-03-23 2023-05-19 Bristol Myers Squibb Co Anticuerpos anti-ccr8 para el tratamiento del cancer
PE20230414A1 (es) 2020-03-24 2023-03-07 Genentech Inc Agentes de fijacion a tie2 y metodos de uso
ES2973425T3 (es) 2020-03-26 2024-06-20 Univ Vanderbilt Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2)
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
CN120058957A (zh) 2020-03-30 2025-05-30 国立大学法人三重大学 双特异性抗体
CA3170570A1 (en) 2020-04-01 2021-10-07 James J. KOBIE Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
JP7744330B2 (ja) 2020-04-01 2025-09-25 協和キリン株式会社 抗体組成物
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
IL297541A (en) 2020-04-24 2022-12-01 Genentech Inc Methods for using anti-cd79b immunoconjugates
CA3172880A1 (en) 2020-04-27 2021-11-04 Sotirios Tsimikas Isoform-independent antibodies to lipoprotein(a)
US11634477B2 (en) 2020-04-28 2023-04-25 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
US20230183354A1 (en) 2020-04-30 2023-06-15 Sairopa B.V. Anti-cd103 antibodies
IL297830A (en) 2020-05-03 2023-01-01 Levena Suzhou Biopharma Co Ltd Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
JP2023525053A (ja) 2020-05-12 2023-06-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
WO2021228091A1 (zh) 2020-05-12 2021-11-18 正大天晴药业集团股份有限公司 St2抗原结合蛋白
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
JP2023528235A (ja) 2020-05-17 2023-07-04 アストラゼネカ・ユーケイ・リミテッド ＳＡＲＳ－ＣｏＶ－２抗体、並びにこれを選択及び使用する方法
US20240043504A1 (en) 2020-05-26 2024-02-08 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
WO2021238886A1 (en) 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
US11787861B2 (en) 2020-05-29 2023-10-17 23Andme, Inc. Anti-CD200R1 antibodies and methods of use thereof
TW202210515A (zh) 2020-06-02 2022-03-16 美商當康生物科技有限公司 抗ｃｄ３９之構築體及其用途
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
EP4161960A1 (en) 2020-06-03 2023-04-12 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
JP2023529206A (ja) 2020-06-12 2023-07-07 ジェネンテック， インコーポレイテッド がん免疫療法のための方法及び組成物
CA3181820A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
JP2023531222A (ja) 2020-06-22 2023-07-21 アルミラル・ソシエダッド・アノニマ 抗ｉｌ－３６抗体およびその使用方法
US12497463B2 (en) 2020-06-23 2025-12-16 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-CD38 antibody and use thereof
MX2022016322A (es) 2020-06-25 2023-01-24 Merck Sharp & Dohme Llc Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413.
JP2023532197A (ja) 2020-06-30 2023-07-27 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ７０抗体及びその応用
KR20230041023A (ko) 2020-07-17 2023-03-23 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 제조 방법
KR20230042055A (ko) 2020-07-20 2023-03-27 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘주게이트와 her 이량체화 저해제의 조합
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN116783215A (zh) 2020-07-29 2023-09-19 当康生物技术有限责任公司 抗cd93构建体及其用途
WO2022029080A1 (en) 2020-08-03 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
WO2022031749A1 (en) 2020-08-03 2022-02-10 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
WO2022029660A1 (en) 2020-08-05 2022-02-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
WO2022031876A1 (en) 2020-08-07 2022-02-10 Genentech, Inc. Flt3 ligand fusion proteins and methods of use
CN116234577A (zh) 2020-08-10 2023-06-06 阿斯利康(英国)有限公司 用于治疗和预防covid-19的sars-cov-2抗体
KR20230050389A (ko) 2020-08-13 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 Il-2를 관심 표적 세포로 재지시하는 방법
EP4196162A1 (en) 2020-08-14 2023-06-21 AC Immune SA Humanized anti-tdp-43 binding molecules and uses thereof
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
IL300694A (en) 2020-09-01 2023-04-01 Chugai Pharmaceutical Co Ltd A pharmaceutical preparation for the prevention and/or treatment of dialysis pruritus that includes an IL-31 antagonist as an active ingredient
EP4211165A1 (en) 2020-09-14 2023-07-19 Ichnos Sciences SA Antibodies that bind to il1rap and uses thereof
AU2021348613A1 (en) 2020-09-28 2023-06-08 Angitia Incorporated Limited Anti-sclerostin constructs and uses thereof
KR20230104611A (ko) 2020-09-30 2023-07-10 드렌 바이오, 인크. 항-cd94 항체 및 이의 사용 방법
EP4222172A1 (en) 2020-09-30 2023-08-09 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
JP2023544407A (ja) 2020-10-05 2023-10-23 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225373A4 (en) 2020-10-07 2025-01-08 Dren Bio, Inc. ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
KR20230086765A (ko) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
WO2022081718A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
JP2023545566A (ja) 2020-10-20 2023-10-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－１軸結合アンタゴニストとｌｒｒｋ２阻害剤との併用療法
WO2022084400A1 (en) 2020-10-20 2022-04-28 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
WO2022090801A2 (en) 2020-10-26 2022-05-05 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2022098870A1 (en) 2020-11-04 2022-05-12 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
US20220153842A1 (en) 2020-11-04 2022-05-19 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
MX2023005130A (es) 2020-11-04 2023-05-25 Genentech Inc Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
AU2021374083A1 (en) 2020-11-06 2023-06-01 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
EP4240769A1 (en) 2020-11-06 2023-09-13 Bristol-Myers Squibb Company Dosing and administration of non-fucosylated anti-ctla-4 antibody as monotherapy
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
KR20230106645A (ko) 2020-11-11 2023-07-13 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 항 SIRPα 항체의 조합
CA3198382A1 (en) 2020-11-12 2022-05-19 Michiko Yamato Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
CN116917318A (zh) 2020-11-20 2023-10-20 法国国家健康和医学研究院 抗cd25抗体
WO2022106663A1 (en) 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
TW202235431A (zh) 2020-11-25 2022-09-16 美商艾希利歐發展股份有限公司 腫瘤特異性可裂解連接子
WO2022120064A1 (en) 2020-12-03 2022-06-09 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20240131064A1 (en) 2020-12-11 2024-04-25 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
US20240299539A1 (en) 2020-12-17 2024-09-12 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
JP2024500920A (ja) 2020-12-23 2024-01-10 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
EP4271791A2 (en) 2020-12-31 2023-11-08 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
WO2022148412A1 (zh) 2021-01-08 2022-07-14 北京韩美药品有限公司 特异性结合cd47的抗体及其抗原结合片段
JP7744991B2 (ja) 2021-01-08 2025-09-26 北京韓美薬品有限公司 ４－１ｂｂと特異的に結合する抗体及びその抗原結合フラグメント
CN117425500A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗dll3抗体-药物缀合物
EP4277664A1 (en) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
AU2022212599A1 (en) 2021-01-28 2023-08-17 Universität Ulm Method and means for modulating b-cell mediated immune responses
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
US20240076373A1 (en) 2021-01-28 2024-03-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2022165266A1 (en) 2021-01-28 2022-08-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
AU2022221297A1 (en) 2021-02-09 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
CA3210753A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
US20240226295A9 (en) 2021-02-15 2024-07-11 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
EP4301467A1 (en) 2021-03-01 2024-01-10 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
CA3209364A1 (en) 2021-03-01 2022-09-09 Jennifer O'neil Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
EP4301418A1 (en) 2021-03-03 2024-01-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates comprising an anti-bcma antibody
EP4301138A2 (en) 2021-03-05 2024-01-10 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
CN117715933A (zh) 2021-03-05 2024-03-15 当康生物技术有限责任公司 抗vista的构建体及其用途
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
WO2022192898A2 (en) 2021-03-10 2022-09-15 Immunowake Inc. Immunomodulatory molecules and uses thereof
TW202300521A (zh) 2021-03-15 2023-01-01 美商建南德克公司 治療狼瘡性腎炎的組成物及方法
WO2022195028A2 (en) 2021-03-18 2022-09-22 Medimmune Limited Therapeutic binding molecules
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
TW202304480A (zh) 2021-03-19 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
EP4313122A1 (en) 2021-03-23 2024-02-07 Iovance Biotherapeutics, Inc. Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2022200303A1 (en) 2021-03-23 2022-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of t cell-lymphomas
JP2024511424A (ja) 2021-03-25 2024-03-13 ダイナミキュア バイオテクノロジー エルエルシー 抗ｉｇｆｂｐ７構築物およびその使用
US20220313806A1 (en) 2021-03-25 2022-10-06 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
IL305847A (en) 2021-03-26 2023-11-01 Innate Pharma Multispecific proteins that contain a binding site for NKP46, a binding site for a cancer antigen that is fused to a cytokine to attract NK cells
KR20230162597A (ko) 2021-03-29 2023-11-28 다이이찌 산쿄 가부시키가이샤 안정적인 다중 특이성 분자 및 그 이용
US20240382592A1 (en) 2021-04-09 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of anaplastic large cell lymphoma
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
TW202308669A (zh) 2021-04-19 2023-03-01 美商艾歐凡斯生物治療公司 嵌合共刺激性受體、趨化激素受體及彼等於細胞免疫治療之用途
WO2022223651A1 (en) 2021-04-23 2022-10-27 F. Hoffmann-La Roche Ag Prevention or mitigation of nk cell engaging agent-related adverse effects
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4334343A2 (en) 2021-05-06 2024-03-13 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
CA3218170A1 (en) 2021-05-12 2022-11-17 Jamie Harue HIRATA Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
TW202306993A (zh) 2021-05-14 2023-02-16 美商建南德克公司 Ｔｒｅｍ２之促效劑
US20240269180A1 (en) 2021-05-17 2024-08-15 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2022245877A1 (en) 2021-05-17 2022-11-24 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
US20240239875A1 (en) 2021-05-17 2024-07-18 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
JP2024521187A (ja) 2021-05-28 2024-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ガンの治療のための組み合わせ療法
TW202306994A (zh) 2021-06-04 2023-02-16 日商中外製藥股份有限公司 抗ddr2抗體及其用途
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CA3216220A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
US20250002601A1 (en) 2021-06-09 2025-01-02 Innate Pharma Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
WO2022258662A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
US12227574B2 (en) 2021-06-17 2025-02-18 Amberstone Biosciences, Inc. Anti-CD3 constructs and uses thereof
AU2022294106A1 (en) 2021-06-18 2024-01-25 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
CA3219360A1 (en) 2021-06-22 2022-12-29 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa
EP4360648A4 (en) 2021-06-23 2025-10-08 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
JPWO2022270524A1 (show.php) 2021-06-23 2022-12-29
CR20240026A (es) 2021-06-25 2024-03-14 Chugai Pharmaceutical Co Ltd Anticuerpo anti-ctla-4
CA3220353A1 (en) 2021-06-25 2022-12-29 Chugai Seiyaku Kabushiki Kaisha Use of anti-ctla-4 antibody
MX2023013915A (es) 2021-06-29 2024-01-25 Seagen Inc Métodos para tratar el cáncer con una combinación de un anticuerpo anti-cd70 no fucosilado y un antagonista de cd47.
US20250382364A1 (en) 2021-07-01 2025-12-18 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
US20250011448A1 (en) 2021-07-08 2025-01-09 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
JP2024525769A (ja) 2021-07-14 2024-07-12 舒泰神（北京）生物製薬股フン有限公司 Ｃｄ４０を特異的に認識する抗体およびその使用
WO2023287875A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
MX2024000501A (es) 2021-07-14 2024-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a hgfr y egfr, y su uso farmaceutico.
CA3226111A1 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
JP2024526880A (ja) 2021-07-22 2024-07-19 ジェネンテック， インコーポレイテッド 脳標的化組成物及びその使用方法
EP4378476A4 (en) 2021-07-27 2025-07-23 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
US20250325663A1 (en) 2021-07-27 2025-10-23 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
CA3226942A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3227515A1 (en) 2021-08-03 2023-02-09 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
KR20240049815A (ko) 2021-08-13 2024-04-17 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Ccr2-발현 세포에 대한 세포독성 표적화 키메라
EP4384224A1 (en) 2021-08-13 2024-06-19 GlaxoSmithKline Intellectual Property Development Limited Cytotoxicity targeting chimeras
WO2023019239A1 (en) 2021-08-13 2023-02-16 Genentech, Inc. Dosing for anti-tryptase antibodies
JP2024534067A (ja) 2021-08-19 2024-09-18 エフ． ホフマン－ラ ロシュ アーゲー 多価抗バリアントｆｃ領域抗体および使用方法
WO2023027177A1 (ja) 2021-08-26 2023-03-02 協和キリン株式会社 Ｃｄ１１６およびｃｄ１３１に結合するバイスペシフィック抗体
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
TW202325727A (zh) 2021-08-30 2023-07-01 美商建南德克公司 抗聚泛素多特異性抗體
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP2024533234A (ja) 2021-09-06 2024-09-12 ジェンマブ エー／エス Ｃｄ２７に結合する能力を有する抗体、そのバリアントおよびその使用
US20240424097A1 (en) 2021-09-09 2024-12-26 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
KR20240095534A (ko) 2021-09-15 2024-06-25 다이이찌 산쿄 가부시키가이샤 화학요법 내성 암의 치료 방법에서 사용하기 위한 항체-약물 접합체
ES3047544T3 (en) 2021-09-16 2025-12-03 Aboleris Pharma Anti-human cd45rc binding domains and uses thereof
WO2023044272A1 (en) 2021-09-17 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
US20250000903A1 (en) 2021-09-24 2025-01-02 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
JP2024534661A (ja) 2021-09-30 2024-09-20 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗ｂ７－ｈ３抗体及びその応用
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
EP4412713A1 (en) 2021-10-05 2024-08-14 GlaxoSmithKline Intellectual Property Development Ltd Combination therapies for treating cancer
EP4412711A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
KR20240082388A (ko) 2021-10-08 2024-06-10 추가이 세이야쿠 가부시키가이샤 프리필드 시린지 제제의 조제 방법
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
JPWO2023068226A1 (show.php) 2021-10-18 2023-04-27
TW202331735A (zh) 2021-10-27 2023-08-01 美商艾歐凡斯生物治療公司 協調用於患者特異性免疫療法之細胞之製造的系統及方法
AU2022379952A1 (en) 2021-11-05 2024-05-16 Mab Biotec, Inc. Monoclonal antibodies against carcinoembryonic antigens, and their uses
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
JP2024544867A (ja) 2021-11-10 2024-12-05 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ８腫瘍浸潤リンパ球を利用する拡張治療の方法
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
MX2024005680A (es) 2021-11-16 2024-05-30 Genentech Inc Metodos y composiciones para tratar lupus eritematoso sistemico (sle) con mosunetuzumab.
TW202334202A (zh) 2021-11-16 2023-09-01 瑞士商Ａｃ免疫有限公司 用於治療和診斷的新分子
WO2023089527A1 (en) 2021-11-18 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
CN118159286A (zh) 2021-11-25 2024-06-07 正大天晴药业集团股份有限公司 抗Siglec-15抗体及其应用
JP2024543916A (ja) 2021-11-25 2024-11-26 ヴェラクサ バイオテック ゲーエムベーハー 遺伝暗号拡張を利用した部位特異的結合によって調製された改良された抗体ペイロード複合体（ａｐｃ）
EP4186529B1 (en) 2021-11-25 2025-07-09 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
EP4442828A4 (en) 2021-11-30 2025-11-12 Daiichi Sankyo Co Ltd Masked antibodies cleavable by protease
EP4445911A4 (en) 2021-12-06 2025-10-22 Beijing Solobio Genetechnology Co Ltd BISPECIFIC ANTIBODY THAT BINDS SPECIFICALLY TO KLEBSIELLA PNEUMONIAE O1 AND O2 ANTIGENS AND COMPOSITION
US20250051440A1 (en) 2021-12-14 2025-02-13 Institut National de la Santé et de la Recherche Médicale Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
KR20240116755A (ko) 2021-12-17 2024-07-30 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
WO2023109901A1 (en) 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use
EP4456922A1 (en) 2021-12-28 2024-11-06 AstraZeneca UK Limited Combination of antibody-drug conjugate and atr inhibitor
US20250161305A1 (en) 2021-12-28 2025-05-22 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy
EP4469159A1 (en) 2022-01-27 2024-12-04 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
US20250170255A1 (en) 2022-02-09 2025-05-29 Daiichi Sankyo Company, Limited Environmentally-responsive masked antibody and use thereof
WO2023153471A1 (ja) 2022-02-09 2023-08-17 国立研究開発法人医薬基盤・健康・栄養研究所 Ｆｃｒｌ１に結合する抗体又は該抗体断片
JP2025506172A (ja) 2022-02-10 2025-03-07 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ コロナウイルスを広く標的とするヒトモノクローナル抗体
WO2023153876A1 (ko) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
EP4479426A1 (en) 2022-02-16 2024-12-25 AC Immune SA Humanized anti-tdp-43 binding molecules and uses thereof
JP2025508739A (ja) 2022-02-18 2025-04-10 ラクテン・メディカル，インコーポレイテッド 抗プログラム細胞死リガンド１（ｐｄ－ｌ１）抗体分子、それをコードするポリヌクレオチド、および使用方法
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023161877A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for integrin avb6-expressing cells
IL314898A (en) 2022-02-25 2024-10-01 Intellectual Property Development Limited Glaxosmithkline Cytotoxic target chimeras for cells expressing C-C as a cytokine
WO2023161875A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
WO2023161879A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
WO2023161878A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for folate receptor-expressing cells
WO2023161881A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
WO2023161876A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for cxcr3-expressing cells
WO2023173026A1 (en) 2022-03-10 2023-09-14 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
US20250297018A1 (en) 2022-03-15 2025-09-25 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CA3255411A1 (en) 2022-03-16 2025-03-04 Daiichi Sankyo Company, Limited COMBINATION OF MULTISPECIFIC MOLECULES AND AN IMMUNE CHECKPOINT INHIBITOR
EP4493933A1 (en) 2022-03-16 2025-01-22 AstraZeneca UK Limited A scoring method for an anti-trop2 antibody-drug conjugate therapy
US20240103010A1 (en) 2022-03-18 2024-03-28 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
EP4496631A1 (en) 2022-03-23 2025-01-29 F. Hoffmann-La Roche AG Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023179740A1 (en) 2022-03-25 2023-09-28 Shanghai Henlius Biotech , Inc. Anti-msln antibodies and methods of use
EP4499227A1 (en) 2022-03-26 2025-02-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Bispecific antibodies to hiv-1 env and their use
US20250197483A1 (en) 2022-03-28 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
TW202405009A (zh) 2022-03-30 2024-02-01 瑞士商諾華公司 使用抗利尿鈉肽受體１（ｎｐｒ１）抗體治療障礙之方法
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2025513799A (ja) 2022-04-08 2025-04-30 エイシー イミューン ソシエテ アノニム 抗ｔｄｐ－４３結合分子
US20250231193A1 (en) 2022-04-11 2025-07-17 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
EP4508087A1 (en) 2022-04-13 2025-02-19 Genentech, Inc. Pharmaceutical compositions of therapeutic proteins and methods of use
TW202404637A (zh) 2022-04-13 2024-02-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
CA3243581A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THAT BIND PANSPECIFICALLY TO GREMLIN-1 AND GREMLIN-2 AND RELATED USES
JP2025513620A (ja) 2022-04-27 2025-04-24 第一三共株式会社 抗体－薬物コンジュゲートとｅｚｈ１阻害剤および／またはｅｚｈ２阻害剤との組合せ
CR20240528A (es) 2022-04-29 2025-04-04 Astrazeneca Uk Ltd Anticuerpos contra el sars-cov-2 y métodos para utilizarlos
EP4514383A1 (en) 2022-04-29 2025-03-05 23Andme, Inc. Antigen binding proteins
PE20242350A1 (es) 2022-05-03 2024-12-16 Genentech Inc Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
WO2023217068A1 (zh) 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
EP4522202A1 (en) 2022-05-10 2025-03-19 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
CA3251472A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. DOSAGE FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
CN119403829A (zh) 2022-05-11 2025-02-07 第一三共株式会社 对于肿瘤抗原特异性的抗体和cd47抑制剂的组合
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
EP4531927A1 (en) 2022-05-24 2025-04-09 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
JPWO2023234426A1 (show.php) 2022-06-03 2023-12-07
CN119677542A (zh) 2022-06-03 2025-03-21 Ｕｂｅ株式会社 抗体-多药物缀合物前体及其合成中间体
KR20250022049A (ko) 2022-06-07 2025-02-14 제넨테크, 인크. 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
US20250382354A1 (en) 2022-06-08 2025-12-18 Institute For Research In Biomedicine (Irb) Cross-specific antibodies, uses and methods for discovery thereof
AU2023286645A1 (en) 2022-06-23 2025-01-16 Fortvita Biologics (Singapore) Pte.Ltd. Bispecific antibody binding egfr and b7-h3
CN119486758A (zh) 2022-06-30 2025-02-18 东丽株式会社 癌的治疗和/或预防用药物组合物
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
EP4551681A1 (en) 2022-07-06 2025-05-14 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
CN119585308A (zh) 2022-07-13 2025-03-07 基因泰克公司 针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
EP4558524A1 (en) 2022-07-19 2025-05-28 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202417503A (zh) 2022-07-19 2024-05-01 美商舒泰神（加州）生物科技有限公司 特異性識別ｂ和ｔ淋巴細胞衰減器（ｂｔｌａ）的抗體及其應用
WO2024018046A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
CR20250056A (es) 2022-07-22 2025-03-19 Genentech Inc Moléculas de unión al antígeno anti-steap1 y sus usos.
EP4558529A1 (en) 2022-07-22 2025-05-28 Bristol-Myers Squibb Company Antibodies binding to human pad4 and uses thereof
WO2024026496A1 (en) 2022-07-28 2024-02-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
KR20250040960A (ko) 2022-07-28 2025-03-25 아스트라제네카 유케이 리미티드 항체-약물 접합체 및 이중특이적 체크포인트 억제제의 조합
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
EP4565329A1 (en) 2022-08-01 2025-06-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4565330A1 (en) 2022-08-05 2025-06-11 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors
WO2024031032A1 (en) 2022-08-05 2024-02-08 Bristol-Myers Squibb Company Anti-ctla-4 antibodies for treatment of kras mutant cancers
EP4565331A1 (en) 2022-08-05 2025-06-11 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors
CN119698274A (zh) 2022-08-19 2025-03-25 亿一生物医药开发(上海)有限公司 包含g-csf的制剂及其用途
CA3265385A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DLL3 BINDING MOLECULES AND THEIR USES
AU2023329558A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20250052364A (ko) 2022-08-24 2025-04-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4578459A1 (en) 2022-08-24 2025-07-02 Toray Industries, Inc. Pharmaceutical product for treatment and/or prevention of cancer
WO2024044675A1 (en) 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
WO2024042112A1 (en) 2022-08-25 2024-02-29 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and uses thereof
AU2023329484A1 (en) 2022-08-26 2025-02-20 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
EP4582100A1 (en) 2022-08-30 2025-07-09 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4582101A1 (en) 2022-08-30 2025-07-09 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN120153254A (zh) 2022-09-01 2025-06-13 基因泰克公司 膀胱癌的治疗和诊断方法
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
EP4587123A1 (en) 2022-09-15 2025-07-23 Avidicure IP B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
CN119998321A (zh) 2022-09-27 2025-05-13 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
EP4602372A1 (en) 2022-10-12 2025-08-20 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies
JP2025535386A (ja) 2022-10-20 2025-10-24 北京三▲諾▼佳邑生物技▲術▼有限▲責▼任公司 ＴＲＡＩＬまたはＦａｓＬに特異的に結合する抗体の組み合わせおよび二重特異性抗体
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
JP2025537137A (ja) 2022-11-04 2025-11-14 ギリアード サイエンシーズ， インコーポレイテッド 抗ｃｃｒ８抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法
TW202434285A (zh) 2022-11-07 2024-09-01 國立大學法人大阪大學 與異常蛋白質之聚集體形成相關之疾病的預防或治療劑
AU2023375342A1 (en) 2022-11-08 2025-04-24 F. Hoffmann-La Roche Ag Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100200A1 (en) 2022-11-09 2024-05-16 Cis Pharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
WO2024107752A2 (en) 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules
KR20250106304A (ko) 2022-11-17 2025-07-09 사노피 Ceacam5 항체-약물 접합체 및 이의 사용 방법
IL320733A (en) 2022-11-21 2025-07-01 Iovance Biotherapeutics Inc Two-dimensional processes for expanding tumor-infiltrating lymphocytes and treatments thereof
EP4623073A2 (en) 2022-11-21 2025-10-01 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
EP4622677A1 (en) 2022-11-24 2025-10-01 BeiGene Switzerland GmbH Anti-cea antibody drug conjugates and methods of use
CN120265651A (zh) 2022-11-25 2025-07-04 中外制药株式会社 用于生产蛋白质的方法
TW202440169A (zh) 2022-11-30 2024-10-16 日商第一三共股份有限公司 抗體-藥物結合物與dnmt抑制劑之組合
EP4634226A1 (en) 2022-12-16 2025-10-22 Pheon Therapeutics Ltd Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
WO2024137381A1 (en) 2022-12-19 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies for treating sars-cov-2 infection
WO2024135809A1 (ja) 2022-12-23 2024-06-27 東レ株式会社 癌の治療及び／又は予防のための医薬品
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
CN120603850A (zh) 2023-01-19 2025-09-05 广州百济神州生物制药有限公司 抗cmet抗体及使用方法
CN120548364A (zh) 2023-01-27 2025-08-26 第一三共株式会社 抗lrrc15抗体
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
WO2024182443A2 (en) 2023-02-27 2024-09-06 Compugen Ltd. Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
KR20250167153A (ko) 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
WO2024183635A1 (en) 2023-03-03 2024-09-12 Beigene, Ltd. Muc1 and cd16a antibodies and methods of use
CN120936627A (zh) 2023-03-03 2025-11-11 广州百济神州生物制药有限公司 Muc1抗体及使用方法
AR132041A1 (es) 2023-03-03 2025-05-21 Beigene Switzerland Gmbh Anticuerpos cd16a y métodos de uso
WO2024184810A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184812A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 antibodies and methods of use
AR132062A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cd3 y métodos de uso
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
CN120813389A (zh) 2023-03-14 2025-10-17 第一三共株式会社 抗cdh6抗体-药物缀合物和vegf抑制剂的组合
AU2024249123A1 (en) 2023-03-29 2025-05-15 Daiichi Sankyo Company, Limited Anti-cd25 antibody and anti-cd25 antibody-drug conjugate
FR3147278A1 (fr) 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
CN121013863A (zh) 2023-03-31 2025-11-25 艾菲赛尔治疗株式会社 Tnfr2结合多肽及使用方法
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
CN120916791A (zh) 2023-03-31 2025-11-07 第一三共株式会社 抗CDH6抗体-药物缀合物与HIF-2α抑制剂的组合
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024214685A1 (ja) 2023-04-10 2024-10-17 第一三共株式会社 抗ｂ７－ｈ３抗体－薬物コンジュゲートとａｔｒ阻害剤又はａｔｍ阻害剤との組み合わせ
WO2024212827A1 (en) 2023-04-12 2024-10-17 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
WO2024218361A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Bispecific cytotoxicity targeting chimeras
US20240358847A1 (en) 2023-04-24 2024-10-31 Merck Sharp & Dohme Llc Trop2 binders and conjugates thereof
AU2024270136A1 (en) 2023-05-05 2025-11-20 Otsuka Pharmaceutical Co., Ltd. Anti-il1rap antibodies
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2024268933A1 (en) 2023-05-10 2025-11-20 Chugai Seiyaku Kabushiki Kaisha Methods and compositions for treating cancer
US12410258B2 (en) 2023-05-12 2025-09-09 Ganmab A/S Antibodies capable of binding to OX40, variants thereof and uses thereof
WO2024243355A1 (en) 2023-05-24 2024-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
WO2024263845A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Treatment of multiple myeloma
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025002410A1 (en) 2023-06-30 2025-01-02 Evive Biotechnology (Shanghai) Ltd G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025024233A1 (en) 2023-07-21 2025-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies that broadly target coronaviruses
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
US20250051434A1 (en) 2023-08-11 2025-02-13 Merck Sharp & Dohme Llc Monovalent interleukin 12 (il-12) heterodimeric fc proteins
WO2025038492A1 (en) 2023-08-11 2025-02-20 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025045251A2 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Multispecific constructs comprising anti-factor d moiety
WO2025064539A1 (en) 2023-09-19 2025-03-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Herv-e antibodies and methods of their use
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025068957A1 (en) 2023-09-29 2025-04-03 Novartis Ag Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
WO2025085489A1 (en) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
TW202523359A (zh) 2023-10-24 2025-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025099280A1 (en) 2023-11-08 2025-05-15 Oxion Biologics Ab Improved anti-ox40l antibodies
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025111402A1 (en) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anti-amyloid beta antibodies and related compositions and methods thereof
WO2025117384A1 (en) 2023-12-01 2025-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing influenza hemagglutinin stem-directed antibodies
WO2025120513A1 (en) 2023-12-05 2025-06-12 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025122835A2 (en) * 2023-12-08 2025-06-12 Eli Lilly And Company Methods of producing fc-containing proteins
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
TW202535935A (zh) 2023-12-20 2025-09-16 美商艾普吉醫療股份有限公司 結合介白素13之抗體之醫藥組合物
WO2025137523A2 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical formulations of antibodies that bind interleukin 13
WO2025137284A2 (en) 2023-12-21 2025-06-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
US20250222125A1 (en) 2024-01-05 2025-07-10 Beigene, Ltd. Anti-FGFR2b Antibodies, Conjugates and Methods of Use
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
WO2025179281A1 (en) 2024-02-23 2025-08-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of cardiovascular disease with antxr1 antibodies
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025184416A1 (en) 2024-02-27 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single-domain antibodies and bispecific antibodies against hiv-1 and their use
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2025238052A1 (en) 2024-05-15 2025-11-20 Institut National de la Santé et de la Recherche Médicale Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
WO2025238187A1 (en) 2024-05-15 2025-11-20 Cis Biopharma Ag Immunoconjugates targeting l1-cam
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
WO2025238587A1 (en) 2024-05-16 2025-11-20 Daiichi Sankyo Company, Limited Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025242909A1 (en) 2024-05-24 2025-11-27 Paul Scherrer Institut CD30-targeting antibody-radioligand conjugates and their therapeutic use
WO2025250969A1 (en) 2024-05-31 2025-12-04 Vertex Pharmaceuticals Incorporated Anti-cd74 antibodies, conjugates and uses thereof
WO2025255353A1 (en) 2024-06-06 2025-12-11 Apogee Therapeutics, Inc. Dosage and administration of an anti-ox40l antibody
WO2025255349A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2025255405A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Anti-fap antibodies and uses thereof
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
CA1142466A (en) * 1979-01-09 1983-03-08 Cesar Milstein Cell lines
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
US4757018A (en) * 1985-02-11 1988-07-12 Hazleton Biotechnologies, Inc. Myeloma cell lines and uses thereof
US4865968A (en) 1985-04-01 1989-09-12 The Salk Institute For Biological Studies DNA sequencing
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US5672502A (en) * 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
JPS62194459A (ja) 1986-02-21 1987-08-26 Sankyo Co Ltd 固相化試薬の安定化剤
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
JPS62244441A (ja) 1986-04-16 1987-10-24 Green Cross Corp:The 抗体固定化担体
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5324663A (en) 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5072502A (en) 1990-04-27 1991-12-17 Yoshida Kogyo K. K. Method and apparatus for applying slide fastener end stop
AU8007791A (en) * 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
JPH06504619A (ja) * 1990-11-23 1994-05-26 ザ ジェネラル ホスピタル コーポレーション 細胞接着蛋白質−糖質相互作用の阻害
US5272070A (en) * 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
DE4110405A1 (de) 1991-03-28 1992-10-01 Birchmeier Walter Prof Dr Verfahren zum nachweis der differenzierung und der invasivitaet von karzinomzellen
CS103091A3 (en) 1991-04-12 1992-10-14 Ustav Organicke Chemie A Bioch Protected substituted benzhydrylamines as shoulders for the synthesis ofpeptides on solid phase, process of their preparation and use
US5558865A (en) 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
FR2682283B1 (fr) 1991-10-10 1994-01-28 Gerard Scortecci Implant dentaire a penetration verticale, concu pour s'adapter aux differents degres de durete de l'os.
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5811517A (en) 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
ES2124308T3 (es) 1992-04-30 1999-02-01 Cor Therapeutics Inc Composicion estable de polipeptidos.
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
JP3154564B2 (ja) 1992-09-07 2001-04-09 科学技術振興事業団 モノクローナル抗体の改変方法
CA2105618C (en) * 1992-09-07 2009-11-03 Kazuyasu Nakamura Humanized antibodies to ganglioside gm2
AU5669494A (en) 1992-11-17 1994-06-08 Yale University Human homolog of the e-cadherin gene and methods based thereon
JPH06189781A (ja) 1992-12-25 1994-07-12 Mitsui Toatsu Chem Inc 培養液中の生理活性タンパク質の安定化方法
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
SG49117A1 (en) * 1993-03-29 1998-05-18 Kyowa Hakko Kogyo Kk Alfa -1, 3-fucosyltransferase
WO1994022478A1 (en) 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
US5422264A (en) 1993-11-12 1995-06-06 Desmos, Inc. Soluble factor stimulation of attachment and hemidesmosome assembly in epithelial cells
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
EP0625574A1 (en) 1993-05-19 1994-11-23 Takeda Chemical Industries, Ltd. Production for biologically active polypeptide
JPH0819397A (ja) 1993-05-19 1996-01-23 Takeda Chem Ind Ltd 生理活性ペプチド製造方法およびその産生細胞
FR2708467B1 (fr) 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
US5585237A (en) * 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
US5558789A (en) 1994-03-02 1996-09-24 University Of Florida Method of applying a laser beam creating micro-scale surface structures prior to deposition of film for increased adhesion
AU694181B2 (en) 1994-03-09 1998-07-16 Abbott Laboratories Humanized milk
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6129913A (en) * 1994-12-23 2000-10-10 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
GB9501683D0 (en) * 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
MX9706827A (es) * 1995-03-10 1997-11-29 Genentech Inc Activacion de receptor por gas6.
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
HUP9701282A3 (en) * 1995-06-07 1999-09-28 Icos Corp Bothell Macrophage derived chemokine and chemokine analogs
US6057115A (en) * 1995-06-16 2000-05-02 Ludwig Institute For Cancer Research Process for producing GM2 specific antibodies
JPH0949836A (ja) 1995-08-08 1997-02-18 Hitachi Ltd 抗体による蛋白質構造の評価方法
JP3946256B2 (ja) * 1995-09-11 2007-07-18 協和醗酵工業株式会社 ヒトインターロイキン５受容体α鎖に対する抗体
CA2241564C (en) 1996-01-08 2013-09-03 Genentech, Inc. Wsx receptor and ligands
DE69736261T2 (de) * 1996-01-24 2007-06-06 Toyo Boseki K.K. Alpha-1-6-fucosyltransferasen
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP2000507812A (ja) 1996-03-12 2000-06-27 ライフ テクノロジーズ，インコーポレイテッド 造血細胞培養栄養補充成分
CA2251465A1 (en) 1996-04-10 1997-10-16 Cytel Corporation Nucleic acids encoding gdp-fucose pyrophosphorylase
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US5728568A (en) * 1996-11-22 1998-03-17 Genetics Institute, Inc. Human GDP-mannose 4,6 dehydratase
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
JP4550947B2 (ja) * 1997-03-19 2010-09-22 協和発酵キリン株式会社 ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CN1259012A (zh) 1997-06-06 2000-07-05 巴斯福股份公司 杀真菌混合物
US6762172B1 (en) 1997-07-17 2004-07-13 Nova Biogenetics, Inc. Water-stabilized organosilane compounds and methods for using the same
JPH11127890A (ja) 1997-10-31 1999-05-18 Kazuo Shimada 糖蛋白質の生産方法
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
WO1999037329A1 (en) 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
HUP0101151A3 (en) 1998-01-23 2004-06-28 Merck Patent Gmbh Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbetha6-integrin attachment to fibnronectin
US6762174B1 (en) 1998-02-24 2004-07-13 Dovetail Technologies, Inc. Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT1071700E (pt) * 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
ES2255765T3 (es) 1998-05-29 2006-07-01 Genentech, Inc. Procedimiento de cultivo de celulas para la produccion de glicoproteinas.
US20020012979A1 (en) 1998-06-08 2002-01-31 Alan Berry Vitamin c production in microorganisms and plants
KR20010083069A (ko) 1998-06-26 2001-08-31 나가야마 오사무 고칼슘혈증치료제
DE69939939D1 (de) * 1998-08-11 2009-01-02 Idec Pharma Corp Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
CN100473417C (zh) 1998-08-31 2009-04-01 安斯泰来美国有限责任公司 Cd2-结合剂调节记忆效应t-细胞的制药用途和组合物
EP1127119A1 (en) 1998-11-03 2001-08-29 Adherex Technologies, Inc. Compounds and methods for modulating claudin-mediated functions
US6238894B1 (en) * 1998-11-04 2001-05-29 Diane Taylor α1,2 fucosyltransferase
BR9917026B1 (pt) 1998-12-09 2010-10-19 método para fabricar glicoproteìnas tendo glicosilação do tipo humano.
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AT408446B (de) 1999-02-18 2001-11-26 Altmann Friedrich Dr Fucosyltransferase-gen
US6540980B1 (en) * 1999-04-02 2003-04-01 Center For Molecular Medicine And Immunology Method of detecting endometriosis
WO2000061739A1 (fr) * 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6350868B1 (en) * 1999-04-26 2002-02-26 University Of North Carolina At Chapel Hill Antisense human fucosyltransferase sequences and methods of use thereof
JP2000308526A (ja) 1999-04-28 2000-11-07 Yoshihiro Inomura 鐙型ブラシ
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
WO2000066160A1 (fr) 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
EP1050307A1 (en) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
PT1180159E (pt) 1999-05-28 2008-12-05 Targeted Genetics Corp Métodos e composições para abaixamento do nível de factor de necrose tumoral (tnf) nos distúrbios associados a tnf
US7504256B1 (en) * 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
WO2001047554A1 (fr) 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
WO2001060405A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6989145B2 (en) 2000-03-03 2006-01-24 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody and antibody fragment
JP5623683B2 (ja) 2000-03-22 2014-11-12 フィトン ホールディングス，リミティド ライアビリティ カンパニー 動物型糖鎖付加機能をもつ植物細胞
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US20030170813A1 (en) * 2000-07-05 2003-09-11 Kenichi Suga Process for producing glycoprotein
JP2004505114A (ja) 2000-08-02 2004-02-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド エリスロポエチンの投与による改良された抗ウイルスおよび抗腫瘍化学療法
US6759045B2 (en) 2000-08-08 2004-07-06 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
WO2002046186A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
CN100430420C (zh) 2001-08-31 2008-11-05 协和发酵工业株式会社 人cdr-移植抗体及其抗体片段
NZ532526A (en) * 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
MXPA04004224A (es) 2001-11-02 2005-03-31 Johnson & Johnson Proteinas del virus sincitial respiratorio, anticuerpos, composiciones, metodos y usos.
AU2002354121A1 (en) 2001-11-28 2003-06-10 Toudai Tlo, Ltd. siRNA Expression System and Method for Producing Functional Gene Knockdown Cell Using the Same
WO2003046173A1 (en) * 2001-11-28 2003-06-05 Center For Advanced Science And Technology Incubation, Ltd. siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003069307A2 (en) * 2002-02-14 2003-08-21 The Johns Hopkins University School Of Medicine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
SI1527100T1 (sl) 2002-03-29 2009-12-31 Schering Corp Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
WO2003084569A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JPWO2003085118A1 (ja) * 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
MXPA04009924A (es) 2002-04-09 2005-07-01 Kyowa Hakko Kogyo Kk Celulas de genoma modificado.
JP4628679B2 (ja) * 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US20050160485A1 (en) * 2003-03-18 2005-07-21 Kyowa Hakko Kogyo Co., Ltd. Mouse in which genome is modified
MXPA05011644A (es) 2003-04-30 2005-12-15 Nastech Pharm Co Subexpresion de claudinas como marcadores de metastasis de tumor.
JP2005058111A (ja) 2003-08-14 2005-03-10 Univ Osaka 糖鎖修飾制御方法
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
US7691810B2 (en) * 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
AU2004280066A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell
ATE437184T1 (de) 2004-01-12 2009-08-15 Applied Molecular Evolution Varianten der fc-region
JP2005224240A (ja) * 2004-01-13 2005-08-25 Kyowa Hakko Kogyo Co Ltd ノックアウト非ヒト動物から樹立された不死化細胞株
US20050208519A1 (en) * 2004-03-12 2005-09-22 Genenews Inc. Biomarkers for diagnosing schizophrenia and bipolar disorder
KR20070029107A (ko) * 2004-06-09 2007-03-13 이데미쓰 고산 가부시키가이샤 안트라센 유도체 및 그것을 이용한 유기 전기발광 소자
US8435530B2 (en) 2004-06-11 2013-05-07 Sbi Biotech Co., Ltd. Methods for suppressing activity of activated interferon-producing cells
US20060262593A1 (en) * 2004-07-27 2006-11-23 Stephane Aouba Magnetic memory composition and method of manufacture
DK2213683T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
US8247371B2 (en) * 2004-10-14 2012-08-21 Yale University Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer
US7150443B2 (en) * 2005-01-18 2006-12-19 Mills Douglas W Control valve for nitrous oxide injection system
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
CA2605781A1 (en) * 2005-05-09 2007-04-12 Glycart Biotechnology Ag Antigen binding molecules having modified fc regions and altered binding to fc receptors
US7923538B2 (en) * 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
JP2009508476A (ja) 2005-08-31 2009-03-05 セントカー・インコーポレーテツド 高められたエフェクター機能をもつ抗体定常領域の製造用の宿主細胞株
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
JP6189781B2 (ja) 2014-04-01 2017-08-30 東京エレクトロン株式会社 熱処理装置、熱処理方法、プログラム、コンピュータ記憶媒体及び基板処理システム

Also Published As

Publication number Publication date
JP4368530B2 (ja) 2009-11-18
JP4850922B2 (ja) 2012-01-11
US20170240647A1 (en) 2017-08-24
US20070166303A1 (en) 2007-07-19
ES2568898T3 (es) 2016-05-05
EP2264166A2 (en) 2010-12-22
CA2369292A1 (en) 2000-10-19
US7687061B2 (en) 2010-03-30
CA2704600C (en) 2016-10-25
DK1914244T3 (da) 2013-07-22
US7708997B2 (en) 2010-05-04
ES2572623T3 (es) 2016-06-01
ES2574826T5 (es) 2020-03-30
US20050272916A1 (en) 2005-12-08
DK2270150T4 (da) 2019-08-26
US7763246B2 (en) 2010-07-27
EP2275540A2 (en) 2011-01-19
EP2264166A3 (en) 2011-06-08
EP2275541B1 (en) 2016-03-23
ES2601882T5 (es) 2021-06-07
ES2571230T3 (es) 2016-05-24
EP2270149A3 (en) 2011-06-08
US20140234300A1 (en) 2014-08-21
DK2278003T4 (da) 2020-08-31
CY2018015I1 (el) 2018-09-05
AU3672800A (en) 2000-11-14
US20070207151A1 (en) 2007-09-06
US20200017593A1 (en) 2020-01-16
EP2270150B2 (en) 2019-08-07
US7651688B2 (en) 2010-01-26
ES2601882T3 (es) 2017-02-16
US20070166300A1 (en) 2007-07-19
ES2420835T3 (es) 2013-08-27
US20070166302A1 (en) 2007-07-19
US20070166305A1 (en) 2007-07-19
US7708992B2 (en) 2010-05-04
US20070166301A1 (en) 2007-07-19
CA2704600A1 (en) 2000-10-19
EP2278003A3 (en) 2011-06-08
EP2270147B1 (en) 2016-08-31
EP2275541A3 (en) 2011-06-08
DK1176195T3 (da) 2013-06-24
US20070166304A1 (en) 2007-07-19
DK2278003T3 (en) 2016-05-17
CY1114164T1 (el) 2016-08-31
DK2270149T3 (en) 2016-05-09
US7682610B2 (en) 2010-03-23
EP2275540A3 (en) 2011-06-08
EP1914244A3 (en) 2008-06-18
DK2275540T3 (en) 2016-05-09
CY1117551T1 (el) 2017-04-26
EP2270150B1 (en) 2016-04-06
US7682611B2 (en) 2010-03-23
EP2278003B1 (en) 2016-03-23
JP2009171976A (ja) 2009-08-06
PT1176195E (pt) 2013-07-18
JP4886010B2 (ja) 2012-02-29
ES2568899T3 (es) 2016-05-05
ES2418360T3 (es) 2013-08-13
DK2270147T4 (da) 2020-08-31
DK2270147T3 (en) 2016-11-21
EP2270149A2 (en) 2011-01-05
EP1176195A4 (en) 2005-03-02
CY1114197T1 (el) 2016-08-31
EP2275540B1 (en) 2016-03-23
EP1914244A2 (en) 2008-04-23
BE2018C020I2 (show.php) 2019-03-06
PT1914244E (pt) 2013-07-26
US7214775B2 (en) 2007-05-08
EP2270147A2 (en) 2011-01-05
US20100196371A1 (en) 2010-08-05
NL300939I2 (nl) 2021-03-18
US20060024800A1 (en) 2006-02-02
EP1914244B1 (en) 2013-05-29
EP2278003B2 (en) 2020-08-05
EP2270150A2 (en) 2011-01-05
CY2018015I2 (el) 2018-09-05
ES2574826T3 (es) 2016-06-22
US10233247B2 (en) 2019-03-19
FR18C1021I1 (fr) 2018-07-13
EP2270147A3 (en) 2011-06-08
ES2572623T5 (es) 2021-06-08
EP3031917A1 (en) 2016-06-15
DK2270150T3 (en) 2016-06-20
EP2278003A2 (en) 2011-01-26
US7655228B2 (en) 2010-02-02
EP2270148A3 (en) 2011-06-08
JP2009275049A (ja) 2009-11-26
US7718175B2 (en) 2010-05-18
EP2270150A3 (en) 2011-06-08
EP1176195A1 (en) 2002-01-30
US8679491B2 (en) 2014-03-25
EP2270148A2 (en) 2011-01-05
LUC00074I2 (en) 2018-07-30
US20050276805A1 (en) 2005-12-15
EP2270147B2 (en) 2020-07-22
CA2369292C (en) 2010-09-21
US20080177043A1 (en) 2008-07-24
WO2000061739A1 (fr) 2000-10-19
EP1176195B1 (en) 2013-05-22
ES2569919T3 (es) 2016-05-13
EP2270149B1 (en) 2016-03-23
DK2275541T3 (en) 2016-05-09
EP2264166B1 (en) 2016-03-23
EP2275541A2 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
FR18C1021I2 (fr) Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
DZ2495A1 (fr) Formule nouvelle de l'oméprazole-s.
FR2725204B1 (fr) 2-hydroxyphenyltriazines comme agents photostabilisants
MA24488A1 (fr) Derives d'acide hexanoique nouveaux .
EP1152521A4 (en) INVERTER CONTROL CIRCUIT
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
IT1292552B1 (it) Dispositivo per l'applicazione di rivestimenti.
DE69836653D1 (de) Korrektur des Vertikalabgleichs
MA26544A1 (fr) Derives de pyrrolopyrrolone comme inhibiteurs d'elastase de neutrophiles
ID21920A (id) 4-6-fluoro-(1h)-indol-3-il-1,2,3,6-tetrahidropirin tersubstitusi untuk pengobatan gangguan cns
IT1308700B1 (it) Procedimento per l'assemblaggio di macchine lavabiancheria
ID16434A (id) Senyawa-senyawa 1,4-dihidropiridin
FR2758444B1 (fr) Boucles d'oreille
MA26481A1 (fr) Derives d'arylsecocholadiene
IT1273539B (it) Hals-fosfoniti come agenti stabilizzanti
EE200000369A (et) Isopropüülmetüül[2-(3-n-propoksüfenoksü)etüül]amiini valmistamise protsess
ITRM940468A0 (it) "impiego di esteruretani per ls riconcia".
SE9903896D0 (sv) Termostat "Esti"
FI960989A0 (fi) Foerfarande foer virkestorkning
NO995939D0 (no) Fremgangsmåte for fremstilling av chirale 3,4-dehydroproliner
FI973824A0 (fi) Foerfarande och maetningsapparat i samband med en traebehandlingsanordning
IT1308156B1 (it) Dispositivo per l'accesso controllato di animali domestici.
FI940088A0 (fi) Regleranordning/reglerdel foer spolvattenmnaengden i en vattenklosett